



**REPORT OF
POPULATION BASED CANCER REGISTRY
AHMEDABAD URBAN AGGLOMERATION AREA
YEAR: 2015-2020**



**NATIONAL CENTRE FOR DISEASE INFORMATICS & RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME
INDIAN COUNCIL OF MEDICAL RESEARCH**

**THE GUJARAT CANCER AND RESEARCH INSTITUTE
(M.P. Shah Cancer Hospital)
STATE CANCER INSTITUTE
(Recognized by Ministry of Health & Family Welfare, Govt. of India)
New Civil Hospital Campus, Medicity, Asarwa, Ahmedabad - 380 016,
GUJARAT, INDIA**

March - 2026

PREFACE

This report presents the consolidated findings of the Population-Based Cancer Registry (PBCR) of Ahmedabad Urban Agglomeration Area for the period 2015–2020. Over the years, the registry has evolved into a strong surveillance system, contributing meaningful insights into the burden and patterns of cancer within the defined population.



The Gujarat Cancer & Research Institute (GCRI) established the PBCR in 2007 under the National Cancer Registry Programme (NCRP), coordinated by the National Centre for Disease Informatics and Research (NCDIR), Indian Council of Medical Research (ICMR). Since its inception, the registry has continuously aligned its processes with national standards, ensuring high-quality, reliable and comparable cancer data.

As the registry matures, it assumes a more defined role in supporting cancer surveillance, research and control strategies. While the integration within the NCRP network has opened avenues for methodological strengthening and collaborative opportunities, it also demands sustained commitment to maintaining data quality and completeness.

The coming years will be critical in determining how effectively the registry contributes to evidence-based cancer control planning and policy formulation. We remain committed to strengthening this initiative and advancing its impact on public health.

Dr. Shashank Pandya

Director GCRI and

Principal Investigator-PBCR Ahmedabad Urban Agglomeration Area Project, NCDIR, ICMR

FOREWORD

It is a privilege to present this report of the Population-Based Cancer Registry (PBCR) of Ahmedabad Urban Agglomeration Area, encompassing data collected over a five-year period from 1st January 2015 to 31st December 2020.



Developed under the framework of the National Cancer Registry Programme (NCRP), this report represents a significant contribution to understanding the epidemiology of cancer in the region. It provides comprehensive and systematically compiled information on cancer incidence, distribution and trends, thereby serving as a vital reference for clinicians, researchers, epidemiologists and health administrators. The data presented herein not only reflect the magnitude and patterns of cancer but also provide a strong foundation for planning targeted cancer control interventions. Furthermore, the registry data facilitate population-based epidemiological research, enabling deeper exploration into risk factors, disease outcomes and health system responses.

I commend the dedicated efforts of Dr. Anand Shah, Co-Investigator and the entire PBCR team for their meticulous work in data collection, validation and analysis. Their commitment has ensured the successful completion of this report.

I am confident that this publication will serve as an invaluable resource for advancing cancer research and strengthening public health strategies.

Dr. Priti R. Sanghavi

Deputy Director, GCRI

ACKNOWLEDGEMENT

We express our sincere gratitude to the heads of institutions, medical professionals, and staff members of government and private hospitals, cancer treatment centers, diagnostic laboratories and private practitioners for their invaluable cooperation in providing data on cancer morbidity and mortality. Their continued support forms the backbone of the registry's functioning.



The data collected through these collaborative efforts are instrumental in understanding the burden and patterns of cancer in the registry area, thereby contributing to epidemiological research, etiological studies and the development of effective cancer control strategies.

We acknowledge with deep appreciation the technical guidance and financial support provided by the National Cancer Registry Programme (NCRP), National Centre for Disease Informatics and Research (NCDIR), and the Indian Council of Medical Research (ICMR), Bengaluru.

We also extend our gratitude to the Gujarat Cancer & Research Institute for providing the necessary institutional framework and continuous encouragement for the functioning and expansion of the cancer registry.

We sincerely appreciate the Government of Gujarat for its proactive initiatives and increasing emphasis on cancer registration, including policy-level support towards systematic reporting of cancer data. Such measures represent an important step toward strengthening cancer surveillance and moving closer to the recognition of cancer as a notifiable disease in the state.

Finally, we express our sincere appreciation to the registry staff whose dedication, diligence and meticulous efforts in data collection, processing and management have made this report possible. Their commitment remains central to the success and sustainability of the registry.

Dr. Anand Shah

Associate Professor, Department of Community Oncology and Medical Records, GCRI and Co-Investigator, PBCR Ahmedabad Urban Agglomeration Area Project, NCDIR-ICMR

**Government of Gujarat Resolution
for reporting of any diagnosed or suspicious case of cancer to
GCRI**

Registration of diagnosed
or suspicious cases of
cancer in Gujarat State

GOVERNMENT OF GUJARAT
Health and Family Welfare Department
No -ICR-102016-521-S
Sachivalaya, Gandhinagar
Date 20 MAY 2016

Preamble

Incidence and mortality of cancer cases are increasing across the globe. While in Gujarat, incidence of oral cavity cancer is highest in India and other cancers are also on rise. All these cancer cases need to be recorded and reported.

The Gujarat Cancer and Research Institute, Ahmedabad being a State Institute for cancer control; Cancer registry is functioning at The Gujarat Cancer and Research Institute since 2004 under the guidance and supervision of National Cancer Registry Programme. This registry data are helpful in measuring comprehensive cancer load, incidence and trend of the disease. It also guides in planning as well as implementation of the cancer control programme.

Resolution:

The Government of Gujarat after due consideration of the matter has found it expedient that a diagnosis or suspicion of cancer cases should be reported to the institute.


Therefore, all hospitals (Government or Private), Nursing Homes, Pathological, Clinical and Radiological Labs, Vital statistics division and Institution imparting medical education and providing diagnosis, treatment and any other health care related facilities shall provide information of diagnosed or suspicious cases of cancer to The Gujarat Cancer and Research Institute, Ahmedabad in prescribed format either in soft copy or hard copy within a period not exceeding three weeks from the date of diagnosis or the date on which the suspicion arose.

P.T.O.....

....2....

The authorized representative of the Gujarat Cancer & Research Institute shall visit the aforesaid hospitals (Government or Private), Nursing Homes, Pathological, Clinical and Radiological Labs, Vital statistics division and Institution imparting medical education and providing diagnosis, treatment and any other health care related facilities twice a month for collection of such information/reports and should be allowed to abstract the medical records of such patients if necessary. All concerned should maintain the strict confidentiality on the identity of the patients suffering from the disease.

By order and in the name of Governor of Gujarat.


(V. G. Vanzara)
Joint Secretary

Health and Family Welfare Department,
Government of Gujarat

To,

- Private Secretary to Hon Minister (Health) Swarnim Sankul-1, Gandhinagar.
- The Commissioner, Health, Dr. Jivaraj Mehta Bhavan, Gandhinagar
- The Additional Director (M.E.) Dr. Jivaraj Mehta Bhavan, Gandhinagar
- The Director, Gujarat Cancer and Research Institute, Ahmedabad.
- All hospitals (Government or Private), Nursing Homes, Pathological, Clinical and Radiological Labs, Vital statistics division and Institution imparting medical education and providing diagnosis, treatment and any other health care related facilities. (Through The Additional Director (M.E.) Dr. Jivaraj Mehta Bhavan, Gandhinagar)
- All District Health Officers
- Section Officer, (V, J, A and E Branches) Health and Family Welfare Deptt. Sachivalay, Gandhinagar.
- Select File
- Branch Collection

PBCR – AHMEDABAD URBAN AGGLOMERATION AREA*

REPORT (YEAR 2015-2020)

Dr. SHASHANK PANDYA

Director GCRI and Principal Investigator-PBCR Ahmedabad Urban Agglomeration Area Project, NCDIR, ICMR

Dr. PRITI R SANGHAVI

Deputy Director, GCRI

Dr. ANAND SHAH

Co – Investigator and Associate Professor

Department of Community Oncology and Medical Records, GCRI

Dr. BEENA BRAHMBHATT

Co – Investigator and Associate Professor, Onco Pathology Dept., GCRI

DEPARTMENT OF COMMUNITY ONCOLOGY AND MEDICAL RECORDS STAFF

Dr. Anand Shah	:	Associate Professor
Dr. Mohit Makwana	:	Assistant Professor
Dr. Rohini Patel	:	Medical Officer
Mr. Himanshu V Patel	:	Medical Record Officer
Mr. Jayesh B Solanki	:	Statistical Assistant
Ms. Vishruti Pandya	:	Statistical Assistant
Ms. Hetal Teli	:	Statistical Assistant
Mr. Ashish Batham	:	Statistical Assistant
Mr. Rohit Cholavia	:	Field Worker

PBCR – AHMEDABAD URBAN AGGLOMERATION AREA PROJECT STAFF

Ms. Prachi Kaloliya	:	Statistician
Mr. Ketan Dobariya	:	Field Supervisor
Mr. Kiritkumar Vasaiya	:	Field Worker
Mr. Sebastian Farmer	:	Field Worker
Mr. Amit D. Rohit	:	Field Worker
Mr. Pratik S. Mahida	:	Field Worker
Mr. Nirav Solanki	:	Field Worker
Mr. Akash Parmar	:	Field Worker

APPENDIX

We are thankful to the following sources of PBCR – Ahmedabad Urban Agglomeration Area who have contributed data and supported in the registry programme.

Sources

AAESHA HOSPITAL	NARAYANA HOSPITAL
AASTHA ONCO ASSOCIATES	NAVJIVAN HOSPITAL
ACCURIS DIGNOSTIC CENTER	PANCHSHIL HOSPITAL
ANANDI SURGICAL HOSPITAL,DHOLKA	PAREKH HOSPITAL
ANANTA HOSPITAL	PHC-KUHA
ANSH CLINIC	PHC-MANIPUR
APOLLO HOSPITAL	PHC-OGNAJ
ASHRAI ONCO ASSOCIATES	POKHRAJ HOSPITAL
B.J.MEDICAL COLLEGE & CIVIL HOSPITAL	RAJASTHAN HOSPITAL
BARWALA NAGAR PALIKA	RIYAN HOSPITAL
CIMS HOSPITAL	RUSHIL CANCER CARE
CITY HOSPITAL	SAFAL SPECIALITY HOSPITAL
COMMUNITY ONCOLOGY CENTRE VASNA	SANJEEVANI HOSPITAL
DHAVAL SURGICAL HOSPITAL	SANKET DIAGNOSTIC PVT. LTD.
DIVA HOSPITAL (DR. AVA DESAI)	SHALBY HOSPITALS
DR NAVINBHAI K PATEL	SHALEEN CANCER CARE
DR. CHIRAG SHAH	SHARDABEN GENERAL HOSPITAL
DR. DHARMESH B. ACHARYA,E.N.T. SURGEON	SHREEJI SPECIALITY HOSPITAL
DR. DILIP SHRINIVASAN	SHREY HOSPITAL
DR. EKTA VALA	SHRI JALARAM SURGICAL HOSPITAL
DR. MUKESH PATEL	SHRI KRISHNA SURGICAL NUSING HOME
DR.ASHIH DAVE,J.K.CANCER HOSPITAL	SHUBHAM LAB
DR.ASHOK PATEL,SHYAM SURGICAL HOSPITAL	SMS HOSPITAL
DR.B.J.PARIKH	SPARSH HOSPITAL
DR.J.T.ZALA , METICULOUS SURGERY AND ENDOSCOPY	STERLING ACCURIS LAB
DR.JAYESH PRAJAPATI,SHUBHAM HOSPITAL	STERLING CANCER CARE
DR.JAYESHBHAI PATEL & DR.NATUBHAI PATEL,ONCO SURGICAL HOSPITAL & ENDOSCOPY	STERLING HOSPITAL
DR.K.C.KOTHARI	SUBHAM CANCER HOSPITAL
DR.S.D.PATEL,DHANDHUKA	SUPRATEC PATHOLOGY LABORATOY
DR.S.V.SHAH,S.P.SURGICAL NURSING HOME	SVP HOSPITAL
DR.SHAILESH S. PATEL,SHIVMANI CANCER HOSPITAL	TAPAN HOSPITAL
DR.SHILIN SHUKLA	TATA MEMORIAL HOSPITAL, MUMBAI
GCS HOSPITAL	THE GUJARAT CANCER & RESEARCH INSTITUE
GOVT.DENTAL COLLEGE AND HOSPITAL	UMIYA CANCER CARE
GULABBAI GENERAL HOSPITAL	UNIPATH LAB

GURUKRUPA PATHOLOGY LABORATORY	VEDANT HOSPITAL
HARIKRUPA ORTHOPADIC HOSPITAL	VEJALPUR NAGAR PALIKA
HCG CANCER CARE	ZANISH CANCER CARE
HEAD & NECK HOSPITAL	ZYDUS HOSPITAL
HEM-ONC ASSOCIATES,	
JIVRAJ MEHTA HOSPITAL	
K.D HOSPITAL	
KAIZEN HOSPITAL	
KRISHNA HOSPITAL	
KRISHNA SURGICAL HOSPITAL	
L.G.HOSPITAL	
LAXMI HOSPITAL	
LIFE LINE DIAGNOSTIC CENTER PATHOLOGY LABORATORY & CYTOLOGY CLINIC	
MEDI LINK HOSPITAL	
N.H.L. MUNICIPAL MEDICAL COLLEGE & V.S.GENERAL HOSPITAL	

**PBCR – AHMEDABAD URBAN
YEAR 2015-2020
CONTENTS**

1	Introduction	1
2	Demographic Characteristics of Ahmedabad Urban Agglomeration Area	2
3	Definitions	4
4	Summary	6
5	Comparative study during the year 2015-2020 in Males and Females	7
6	Cancer Registration System	8
7	Population Estimation	11
9	Source of Registration	12
10	Gender wise Distribution of Registered Cancer Cases	13
11	Proportion of Cancers by Broad Age Group	14
12	Age Specific Incidence Rates	15
13	Leading Sites of Cancer in Males and Females	16
14	Tobacco Related Cancers	17
15	Head and Neck Cancers	19
16	Method of Diagnosis	21
17	Cancer Mortality	23
16	Cumulative Rate and Risk	24
17	Appendix (List of Tables)	25

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, affecting both developing and developed nations. According to the Global Cancer Observatory (GLOBOCAN) 2022, approximately 19,976,499 new cancer cases and 9,743,832 cancer-related deaths occur globally each year. In India alone, around 1.41 million new cancer cases and 916,827 deaths are reported annually. Furthermore, projections by GLOBOCAN indicate that the number of cancer cases in India is expected to rise significantly, reaching 2.22 million cases by the year 2040.

The growing burden of cancer poses a major challenge to healthcare systems. Understanding the magnitude, distribution, and determinants of cancer is essential for effective prevention, early detection, treatment, and control strategies. Epidemiology plays a crucial role in this regard by providing scientific evidence on patterns and trends of cancer in populations.

The availability of reliable and comprehensive data on cancer cases is fundamental to addressing the increasing cancer burden. Cancer registries are among the most important tools used to systematically collect, store, analyse, and interpret such data.

The National Cancer Registry Programme (NCRP) was initiated by the Indian Council of Medical Research (ICMR) in December 1981 as a long-term activity to establish a network of cancer registries across the country. According to ICMR, cancer registration is defined as the ongoing systematic collection of data on specific parameters related to cancer, which helps in determining the magnitude and burden of the disease, monitoring trends in incidence, and assessing clinical characteristics of different cancers.

Population Based Cancer Registries (PBCRs) systematically collect data on all new cancer cases occurring within a clearly defined population. These registries obtain information from multiple Sources of Registration (SoR) such as government hospitals, private hospitals, nursing homes, clinics, diagnostic laboratories, imaging centres, hospices, and registrars of births and deaths.

A cancer registry primarily aims at systematic collection of cancer data, storage, analysis & interpretation, periodic report publication and dissemination.

Cancer registration data can be used for understanding cancer patterns, monitoring trends over time, evaluating cancer control programmes, and guiding public health policies. In developing countries like India, PBCR data plays a vital role in planning effective cancer prevention and control strategies.

Population Based Cancer Registry:

The Population Based Cancer Registry (PBCR) – Ahmedabad Urban Agglomeration Area has been functioning since the year 2007 under the network of National Cancer Registry Programme (NCRP) which has evolved into a permanent centre of National Centre for Disease Informatics and Research (NCDIR), ICMR Complex at Bengaluru.

The main objective of PBCR Ahmedabad urban is:

- I. To determine the incidence of different types of cancer in the selected population in Ahmedabad urban Agglomeration area
- II. To analyse the distribution of cancer cases according to age, sex and type of cancer among the registered cases Ahmedabad urban Agglomeration area
- III. To assess the pattern of common cancers and identify the most frequently occurring cancer types in Ahmedabad Urban Agglomeration area

Demographic Characteristics of Ahmedabad Urban Agglomeration Area:

Ahmedabad is the most populous city in the Indian state of Gujarat. Ahmedabad is located near the banks of the Sabarmati River 25 km from the capital of Gujarat, Gandhinagar, also known as its twin city. It is founded in 1411 by Sultan Ahmad Shah. It is a major economic and industrial hub, historically known for its booming textile industry that earned it the nickname “Manchester of India”, and today it contributes significantly to commerce, finance, education and manufacturing in western India. The city combines rich cultural heritage—including historic monuments and traditional architecture—with modern development, and it was designated a UNESCO World Heritage City in 2017.

As per the 2011 Census, the total population of the area was 55.85 lakh, with 29.42 lakh males and 26.42 lakh females. The male–female ratio stands at 899 females per 1000 males, indicating a gender imbalance in the population. The population density is 11,948 persons per square kilometre, reflecting a highly dense urban settlement. According to the 2011 Census, the average literacy rate in Ahmedabad city was 89.62%, with male literacy at 93.96% and female literacy at 84.81%. The registry area covers a total area of 364 square kilometres, comprising 100% urban region.

The registry area covered under AHMEDABAD URBAN is shown in the map given below.

Map of Ahmedabad Urban Agglomeration Area



Definitions

The Ahmedabad Urban Population-Based Cancer Registry (PBCR) includes all invasive cancers diagnosed in residents of the registry area. Cases are coded according to International Classification of Diseases for Oncology (ICD-O) standards.

Incident Cases:

All new cases of cancer diagnosed in a defined population during a specified period are considered as incident cases. Hence all new cases of cancer diagnosed in the defined area of Ahmedabad Urban Agglomeration during the year 2015-20 (1st Jan 2015 to 31st Dec 2020) formed the incident cases.

Incidence Rates:

In general, a rate is defined as frequency of a disease or characteristic, per unit size of population or group in which it is observed. A rate measures the number of events occurring in a defined population in a period, in relation to the size of the population. Rates may be expressed per 1000, per 100000, per million, or other bases dependent on particular circumstances. Rates for cancer are usually expressed per 100,000 populations. The commonly measured types of rates in cancer are Crude Incidence Rate (CIR), Age specific Incidence Rate (ASpR), age adjusted or Standardized Incidence Rate (AAR/ ASR) and Truncated Incidence Rate (TR)

Crude Incidence Rate (CIR):

The CIR can be easily calculated by dividing total number of new cases (C) registered during a year by corresponding population of that year (N) and multiplying the result by 100,000. i.e.

$$\text{CIR} = (C / N) \times 100,000$$

Age Specific Rate (ASpR):

This rate can also be simply calculated by dividing number of cases of a given age-group (Ci) by corresponding population of same age group (Ni) and multiplying result by 100,000

i.e. $\text{ASpR} = (C_i / N_i) \times 100,000$

Age Adjusted/ Standardized Rate (AAR):

One of the most frequently encountered problems in cancer epidemiology is comparison of incidence rates for a particular cancer between two different populations, or for same population over time. If one population is on average younger than other, then even if age specific rates were same in both populations, more cases would appear in older population than in younger. Hence, in order to make rates of cancer comparable between two populations or countries, a world standard population that takes into account such disparities is used to arrive at age adjusted or age standardized rates (AAR). This is calculated according to the direct method (Boyle and Parkin, 1991) by obtaining the age specific rates and applying

these rates to the standard population in that age group. The world standard population approximates the proportional age distribution of the world and is given below:

Age Distribution of World Standard Population (Segi.et.al)

Age Group (in years)	World Standard Population
00-04	12000
05-09	10000
10-14	9000
15-19	9000
20-24	8000
25-29	8000
30-34	6000
35-39	6000
40-44	6000
45-49	6000
50-54	5000
55-59	4000
60-64	4000
65-69	3000
70-74	2000
75+	2000
All Ages	1,00,000

$$AAR = \frac{\sum_{i=1}^A a_i w_i}{\sum_{i=1}^A w_i}$$

Where a_i is the age specific rate in age class i

w_i is the world standard population in age class i

A is the number of age class interval

Truncated Rate (TR):

Truncated Rate (TR) is the rate similar to AAR except that it is calculated for the truncated age group of 35-64 years of age.

Summary

Between 2015 and 2020, a total of 34,930 new cancer cases were registered comprising 19,486 cases in males and 15,444 in females. The Crude Cancer Incidence Rate (CR) was 89.8 per lac population per year for males and 78.5 for females. The Age-Adjusted Rate (AAR) per one lac population was 95.9 for males and 78.1 for females. The truncated incidence rate (TR) was 178.7 per one lac population in males and 159.5 in females. The male-to-female ratio was 1.26:1.

Among males, the most common cancer sites were mouth cancer (4,812 cases, 24.7%), followed by tongue cancer (2,300 cases, 11.8%), lung cancer (1,509 cases, 7.7%), oesophageal cancer (958 cases, 4.9%) and prostate cancer (904 cases, 4.6%).

In females, the leading cancer site was breast cancer (5,355 cases, 34.7%), followed by cervical cancer (1,205 cases, 7.8%), mouth cancer (892 cases, 5.8%), ovarian cancer (821 cases, 5.3%), and tongue cancer (678 cases, 4.4%).

Pediatric cancers (0–14 years) accounted for 1.52% of total cases (532 cases) with a higher incidence in boys (335 cases, 1.72%) compared to girls (197 cases, 1.28%).

Nearly half of all cancers in males (9,540 cases, 48.96%) were tobacco-related, while in females, 18.63% (2,877 cases) were tobacco-related.

The proportion of cases diagnosed microscopically was 97.95% in males and 97.73% in females.

The mortality-to-incidence ratio was 36.95% for both sexes, and 0.01% of cases were registered through Death Certificate Only (DCO).

Comparative study during the year 2015-2020 in Males

Particulars	Year					
	2015	2016	2017	2018	2019	2020
Number of cancer cases and percentage	3107 (57.04%)	3265 (55.50%)	3498 (56.56%)	3730 (55.71%)	3576 (53.57%)	2310 (57.12%)
Crude Incidence Rate	92.4	94.4	98.3	101.8	94.9	59.6
Age Adjusted Incidence Rate	100.37	102.54	106.53	108.29	100.44	61.4
Truncated Incidence Rate	191.4	190.4	196.3	198.6	180.3	122.9
Crude Mortality Rate	15.01	13.69	17.05	18.09	17.2	18.96
Death Certificate Only	0	0	0	0	1 (0.01%)	0
Microscopically Confirmed	3076 (99%)	3228 (98.87%)	3429 (98.03%)	3650 (97.86%)	3440 (96.20%)	2264 (98.01%)

Comparative study during the year 2015-2020 in Females


Particulars	Year					
	2015	2016	2017	2018	2019	2020
Number of cancer cases and percentage	2340 (42.96%)	2618 (44.50%)	2687 (43.44%)	2965 (44.29%)	3100 (46.43%)	1734 (42.88%)
Crude Incidence Rate	77	83.6	83.3	89.2	90.5	49.2
Age Adjusted Incidence Rate	78.01	83.95	83.71	88.49	89.9	47.63
Truncated Incidence Rate	163.9	175.5	169.1	175.3	179.6	99.7
Crude Mortality Rate	12.53	15.06	17.3	19.13	17.52	18.45
Death Certificate Only	0	0	0	0	0	0
Microscopically Confirmed	2319 (99.10%)	2599 (99.27%)	2631 (97.92%)	2915 (98.31%)	2933 (94.61%)	1696 (97.81%)

Cancer Registration System

The physical location of PBCR - Ahmedabad Urban Agglomeration area is based at the Gujarat Cancer and Research Institute (GCRI). At GCRI, trained cancer registry personnel fill the core proforma by direct interview with patient / relative at the time of registration every day.

At GCRI, each and every patient is interviewed and their socio-demographic details are collected at the time of registration. Later, the case records of these patients are obtained by the registry to extract information on clinical items such as method of diagnosis, site of cancer, treatment details etc. The inclusion criteria for registration of cases is that patients who have lived in the defined areas of Ahmedabad Urban for a minimum period of one year at the time of first diagnosis of cancer. Only invasive cancers (5th digit morphology code 3 or 6) are reported. Benign tumors and in-situ cancers are not included for analysis.

i. Working of Registry at the Gujarat Cancer and Research Institute (GCRI):




Besides the base Institution (GCRI), the registry staff visits various sources of registration in coverage area namely all Government hospitals, Private hospitals, Diagnostics centers and Death registration units. They actively pursue and collect information on cancer cases reported.

The record files maintained by the various departments of these hospitals viz. pathology, hematology, radiology and the various specialized surgical and medical wards are also examined. The requisite details obtained for each patient are cross-checked with the information collected from the various departments of the collaborating hospitals to ensure completeness of records. Full information on every cancer patient registered at each and every hospital are thus obtained, irrespective of whether or not the patient is subsequently treated at the particular hospital. Additional information is obtained every time when a cancer patient is re-admitted or re-examined at the institution.

As a result of such data collection from different sources, one and the same patient is sometimes found to be registered at two or more sources. Care is taken to see that multiple entries for the same patients are not made in our records. On the other hand in some instances complete medical information could be obtained only by combining the data obtained from two or more hospitals of the same patient. Patients attending the clinics (outpatient departments) of various hospitals are not included in our registry, except in the case of The Gujarat Cancer and Research Institute, because of a paucity of medical details and information on the residential status, in the record files maintained in the out – patient clinics of general hospitals.


ii. Working of Registry at other than GCRI sources:



For collection of mortality data, help is taken from Ahmedabad Municipal Corporation too along with GCRI and all other sources. Supplementary information about patient could often be captured from the death records maintained by the Vital Statistics Division of Ahmedabad Municipal Corporation. Every cancer death which is not traceable or not matched with registered cases in our files, with same year cancer cases or with previous years cancer cases, is labeled as an 'unmatched death' and the date of death is then taken as the date of first diagnosis, and is so registered in the corresponding year's data file as Death Certificate Only (DCO) cases.

The known residence cases as well as those whose residence addresses are not known; both are recorded in our files after collecting necessary information from the various collaborating institutes. Non-residence cases are not considered.


iii. Working of Registry for collection of Cancer Mortality Data:



Population Estimation

Estimated population for the year 2015-2020, the percentage distribution of the population by five-year age groups and sex for the Ahmedabad Urban Agglomeration area for the year 2015-20 is as mentioned below.

Five Year Age Group	Males		Females	
	n	%	n	%
00-04	1620051	7.47	1444406	7.34
05-09	1752427	8.08	1389326	7.06
10-14	1850070	8.53	1456554	7.41
15-19	1952632	9.0	1570587	7.99
20-24	2107639	9.72	1982029	10.08
25-29	2159237	9.95	2045450	10.4
30-34	1876713	8.65	1759105	8.94
35-39	1616883	7.45	1505551	7.65
40-44	1412149	6.51	1390655	7.07
45-49	1328386	6.12	1331708	6.77
50-54	1188428	5.48	1105986	5.62
55-59	993433	4.58	882988	4.49
60-64	721312	3.33	651250	3.31
65-69	438876	2.02	410375	2.09
70-74	304614	1.4	316724	1.61
75+	367160	1.69	426433	2.17
Total	21690010	100	19669127	100



The population for the year 2015–20 was estimated using the difference distribution method as recommended by the National Cancer Registry Programmed (NCRP) under the National Centre for Disease Informatics and Research (NCDIR).


Sources of Registration

The Ahmedabad Urban Cancer Registry encompasses more than 200 hospitals and private consultants across the metropolitan area. Among these, there are 95 collaborating hospitals, comprising Municipal hospitals, Government hospitals, corporate hospitals and Trust hospitals.

The primary source of cancer data collection is The Gujarat Cancer and Research Institute (GCRI), which serves as the base institution for the registry. GCRI is recognized as a State Cancer Institute (SCI) by the Government of India. Additionally, the Birth & Death department of Ahmedabad Municipal Corporation is an important source for identifying cancer cases.



From the year 2015 to 2020, a total of 18,312 new cancer cases (52.44%) were registered from The Gujarat Cancer and Research Institute, while 16,610 cases (47.56%) were recorded from other sources. Other sources are mainly divided into (1) Sources of Ahmedabad Urban Area and (2) Sources of Ahmedabad District (other than Urban Area) group.

Source	#	%
GCRI	18312	52.44
Other Sources	16610	47.56
Total	34922	100



Gender wise Distribution of Registered Cancer Cases

Males accounted for the majority of registered cases, representing approximately 55.8% of the total cases, while females constituted 44.2%. The findings indicate a higher burden of cancer among males compared to females in the registry population.




Proportion of Cancers by Broad Age Group

In the 35–64 years age group, cancer cases make up 63.73% of total cases in males and 67.33% in females indicating that cancer incidence is highest among the middle-aged population in the registry area.

Among the elderly (aged 65 and above), 26.61% of cases were reported in males and 23.06% in females representing the second largest proportion of cases in both sexes.


Cancer occurrence in younger age groups was comparatively lower. The 15–34 years age group accounted for 7.94% of cases in males and 8.33% in females. The paediatric age group (0–14 years) contributed the smallest proportion with 1.72% among the boys and 1.28% among the girls.



Age specific Incidence Rates

The age-specific incidence rates by five-year age groups and sex for Ahmedabad Urban during the period 2015–2020 as shown in following table.


Age group	Male	Female
0-4	0.58	0.39
05-09	0.64	0.41
10-14	0.5	0.48
15-19	0.95	0.79
20-24	1.27	1.24
25-29	1.95	2.18
30-34	3.78	4.11
35-39	6.63	6.38
40-44	8.68	9.6
45-49	10.15	12.57
50-54	12.36	13.44
55-59	12.27	12.28
60-64	13.65	13.07
65-69	11.21	9.92
70-74	7.7	6.56
75+	7.51	6.45



Age-specific incidence rates among males ranged from 0.50 in the 10–14 years age group to a peak of 13.65 in the 60–64 years age group per 100,000 population. Among females, the rates varied from 0.39 in the 0–4 years age group to a maximum of 13.44 in the 50–54 years age group per 100,000 population.


Leading Sites of Cancer in Males

Mouth (24.56%) and tongue (11.80%) are the most common cancer sites among males, together accounting for approximately 36% of all male cases. Lung cancer ranks third, representing 7.74% of cases followed by esophageal cancer at 4.92%. Prostate cancer is the fifth most common site (4.64%) followed by non-Hodgkin lymphoma (3.03%), laryngeal cancer (2.79%), colon cancer (2.52%) and hypopharyngeal cancer (2.45%).



Leading Sites of Cancer in Females

Among females, breast cancer accounts for the highest proportion of cases (34.67%), making it the most prevalent cancer. The second most common site is cancer of the cervix uteri (7.80%) followed by mouth cancer (5.78%), ovarian cancer (5.32%), and tongue cancer (4.39%). Other leading cancer sites include the oesophagus (3.26%), corpus uteri (3.11%), lung (2.88%) and non-Hodgkin lymphoma (2.46%).





Tobacco related Cancers

For the purpose of comparison with other national cancer registries, cancers of the lip, tongue, mouth, pharynx (excluding the nasopharynx), oesophagus, larynx, lung and urinary bladder were considered tobacco-related cancers (TRCs) in this report. While the International Agency for Research on Cancer (IARC 2004) provides sufficient evidence linking cigarette smoking to cancers of the nasal cavities and sinuses, stomach, liver, kidney, uterine cervix, and myeloid leukemia, these sites are not included here for the sake of consistency with other registries.

Tobacco-related cancers (TRCs) account for 48.96% of all male cancers and 18.63% of all female cancers. Among males, oral cavity cancers are the most prevalent, with mouth cancer (31.25%) forming the largest proportion of TRCs followed by tongue cancer (24.11%) and lung cancer (15.82%). In females, mouth cancer (31%) constitutes the highest proportion of TRCs, followed by tongue cancer (23.57%) and oesophageal cancer (17.48%).

Sites of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	179	1.88	34	1.18
Tongue (C01-02)	2300	24.11	678	23.57
Mouth (C03-06)	2981	31.25	892	31.00
Oropharynx (C10)	145	1.52	17	0.59
Hypopharynx (C12-13)	478	5.01	127	4.41
Pharynx (C14)	152	1.59	25	0.87
Oesophagus (C15)	958	10.04	503	17.48
Larynx (C32)	544	5.70	67	2.33
Lung (C33-34)	1509	15.82	445	15.47
Urinary Bladder (C67)	294	3.08	89	3.09
Total TRCs	9540	48.96	2877	18.63
All Sites	19486	100	15444	100

Following is the graphical presentation of Tobacco Related Cancers in Males and Females:



Head and Neck Cancers



The anatomical sites that are classified under head and neck cancers as per the International Classification of Diseases (ICD-10) are tongue (C01-C02), mouth (C03-C06), tonsil (C09), other oropharynx (C10), nasopharynx (C11), hypopharynx (C12-C13), pharynx unspecified (C14) and Larynx (C32).

Site	Male		Female		Total		M:F
	#	%	#	%	#	%	Ratio
Tongue (C01-C02)	2308	26.48	678	36.31	2986	28.21	3.40:1
Mouth (C03-C06)	4823	55.33	896	47.99	5719	54.03	5.38:1
Tonsil (C09)	207	2.37	29	1.55	236	2.23	7.14:1
Other Oropharynx (C10)	145	1.66	25	1.34	170	1.61	5.80:1
Nasopharynx (C11)	59	0.68	17	0.91	76	0.72	3.47:1
Hypopharynx (C12-C13)	479	5.50	67	3.59	546	5.16	7.15:1
Pharynx Unspecified (C14)	152	1.74	28	1.50	180	1.70	5.43:1
Larynx (C32)	544	6.24	127	6.80	671	6.34	4.28:1
Total	8717	100	1867	100	10584	100	4.67:1
Proportion of H&N cancers to total cancers	19486	44.73	15444	12.09	34930	30.3006	1.26:1

Among head and neck cancers, the highest number of cases were reported for mouth cancer (54.03%), followed by tongue cancer (28.21%) in both sexes. Mouth cancers alone contributed to more than half of the total head and neck cancer burden.

The overall male-to-female (M: F) ratio for head and neck cancers was 4.67:1, indicating a strong male predominance. Among specific sites, the highest M: F ratio was observed in hypopharyngeal cancers (7.15:1), followed closely by tonsil cancers (7.14:1).

Between 2015 and 2020, head and neck (H&N) cancers accounted for 30.30% of all cancer cases. A total of 10,584 cases were reported, with 8,717 cases (44.73%) in males and 1,867 cases (12.09%) in females. The following graphs illustrate the distribution of head and neck cancers by sex.



Method of Diagnosis



The method of diagnosis is crucial in determining the accuracy and reliability of cancer incidence statistics with microscopic confirmation being widely regarded as the most valid diagnostic approach.

From 2015 to 2020, 97.86% of all cancer cases were microscopically confirmed—97.95% among males and 97.73% among females. Of these, histology of the primary site was the most common diagnostic method accounting for 85.51% in males and 88.31% in females. Bone marrow examination followed comprising 5.73% of cases in males and 4.30% in females while histology of metastasis accounted for 5.52% in males and 4.08% in females. Cytological methods contributed a smaller proportion with 1.18% of cases in males and 1.03% in females.

Non-microscopic diagnostic methods were minimal with clinical diagnosis accounting for just 0.24% of cases in males and 0.16% in females. Death Certificate Only (DCO) cases were negligible representing 0.01% in males and none in females.

Method Of Diagnosis	Males		Females	
	n	%	n	%
Microscopic	19087	97.95	15093	97.73
Histology of Primary	16663	85.51	13639	88.31
Bone Marrow	1116	5.73	664	4.3
Histology of Metastasis	1076	5.52	630	4.08
Cytology of Primary	149	0.76	106	0.69
Cytology of Metastasis	81	0.42	52	0.34
Blood Film	2	0.01	2	0.01
X-Ray/Imaging Techniques	281	1.44	269	1.74
Clinical	47	0.24	25	0.16
Others	45	0.23	39	0.25
DCO	1	0.01	0	0
Unknown / Missing	25	0.13	18	0.12
Total	19486	100	15444	100

The following graphs illustrate the Method of Diagnosis by Gender



Cancer Mortality

Mortality statistics have long been a valuable tool in cancer epidemiology, particularly when morbidity data were unavailable. Analyses of mortality across occupational groups have contributed to the identification of several chemical carcinogens. However, with the development of population-based cancer registries and improved availability of morbidity data, the reliance on mortality studies has declined. Additionally, targeted epidemiological field studies have further reduced the importance of mortality data for investigating specific etiological hypotheses.

In PBCR Ahmedabad Urban, cancer mortality data were obtained from death records maintained by the Ahmedabad Municipal Corporation. Between 2015 and 2020, a total of 12,907 cancer deaths were recorded including 7,873 males and 5,034 females. These records were matched with registered cancer morbidity data. The annual crude mortality rate (CMR) and age-adjusted mortality rate (AAMR) per 100,000 population were 36.3 and 38.93 in males, and 25.6 and 25.89 in females respectively. The truncated mortality rates were 74.3 for males and 52.4 for females per 100,000 population. The mortality-to-incidence (M/I) ratio was 40.40% in males and 32.60% in females.

Mortality Indicators	Males	Females
Number of Cancer Mortality	7873	5034
Crude Mortality Rate (CMR) per 1 lac population	36.3	25.6
Age Adjusted Mortality Rate (AAMR) per 1 lac population	38.93	25.89

Cumulative Rate and Cumulative Risk

The Cumulative rate proposed by Day (1987) is another age standardized incidence rate. The Cumulative risk is the probability that an individual will be diagnosed with cancer during a certain age period in the absence of any competing cause of death and assuming that the current trends prevail over the time period.

For practical purposes, Cumulative rate is a good approximation of Cumulative risk over the defined period. It is the sum of age specific incidence rates over a certain age range. It is obtained by adding the annual age-specific incidence rates for each five-year age interval (up to either 64 or 74 years of age or for whatever age group is to be used to calculate the cumulative risk) multiplied by 5 (representing the five-year age interval) times 100/100,000.

$$CuR = \frac{5 \times \sum(ASpR) \times 100}{1,00,000}$$

Cumulative risk is expressed as

Cumulative Risk = $100 \times [1 - \exp(-\text{cumulative rate}/100)]$

Possibility one in number = $(1/\text{Cumulative Risk}) \times 100$

Cumulative risk (%) in 0-74 years:

If one survives up to the age of 74 years, the probability of developing any cancer in men is 1 in 9 and 1 in 12 in women in PBCR Ahmedabad Urban.

List of Tables

PBCR – AHMEDABAD URBAN 2015-2020

No.	NAME OF TABLE
1	Estimated Ahmedabad Urban Agglomeration Area population by Age and Sex : 2015-2020
2	Number of incident Cancers by Five Year Age Group and Site (ICD-10) 2015-2020 Males <i>%= Relative Proportion of Cancers of All Sites</i>
3	Number of incident Cancers by Five Year Age Group and Site (ICD-10) 2015-2020 Females <i>%= Relative Proportion of Cancers of All Sites</i>
4	Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and Truncated (35-64 yrs) (TR) Incidence Rate per 100,000 population :2015-2020 – Males
5	Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and Truncated (35-64 yrs) (TR) Incidence Rate per 100,000 population :2015-2020 – Females
6	Number of Cancer Deaths by Five Year Age Group and Site(ICD-10) 2015-2020 - Males <i>Relative proportion of Cancers of All sites</i>
7	Number of Cancer Deaths by Five Year Age Group and Site(ICD-10) 2015-2020 - Females <i>Relative proportion of Cancers of All sites</i>
8	Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and Truncated (35-64 yrs) (TR) Mortality Rate per 100,000 population :2015-2020 – Males
9	Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and Truncated (35-64 yrs) (TR) Mortality Rate per 100,000 population :2015-2020 – Females
10	Number (#) and Proportion (%) of Cancers by site (ICD-10) and Method of Diagnosis : 2015-2020 – Males
11	Number (#) and Proportion (%) of Cancers by site (ICD-10) and Method of Diagnosis : 2015-2020 – Females
12	Number (#) and Proportion (%) of Cancers by site (ICD-10) and Detailed microscopic Diagnosis : 2015-2020 – Males
13	Number (#) and Proportion (%) of Cancers by site (ICD-10) and Detailed microscopic Diagnosis : 2015-2020 – Females



National Cancer Registry Program

Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020



Estimated Ahmedabad Urban Agglomeration Area population by Age and Sex: 2015-20

Age Group	Males		Females	
	n	%	n	%
00-04	1620051	7.47	1444406	7.34
05-09	1752427	8.08	1389326	7.06
10-14	1850070	8.53	1456554	7.41
15-19	1952632	9	1570587	7.99
20-24	2107639	9.72	1982029	10.08
25-29	2159237	9.95	2045450	10.4
30-34	1876713	8.65	1759105	8.94
35-39	1616883	7.45	1505551	7.65
40-44	1412149	6.51	1390655	7.07
45-49	1328386	6.12	1331708	6.77
50-54	1188428	5.48	1105986	5.62
55-59	993433	4.58	882988	4.49
60-64	721312	3.33	651250	3.31
65-69	438876	2.02	410375	2.09
70-74	304614	1.4	316724	1.61
75+	367160	1.69	426433	2.17
Total	21690010	100	19669127	100



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number of incident Cancers by Five Year Age Group and Site (ICD-10) 2015-20 Males

% = Relative Proportion of Cancers of All Sites

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total	Percentage
C00	Lip	0	0	0	2	0	3	3	12	27	23	21	30	22	16	9	10	1	180	0.92
C01-C02	Tongue	0	1	1	3	14	46	163	262	319	311	326	270	253	168	97	65	1	2301	11.79
C03-C06	Mouth	2	1	1	2	20	84	260	546	688	760	717	602	499	316	183	120	11	4823	24.71
C07-C08	Salivary Gland	0	0	0	0	3	5	1	4	4	5	9	10	12	3	9	4	0	69	0.35
C09	Tonsil	0	0	0	0	2	0	4	10	18	27	35	34	38	19	15	5	0	207	1.06
C10	Oth. Oropharynx	0	0	0	0	0	0	3	8	10	16	21	27	24	17	9	10	0	145	0.74
C11	Nasopharynx	1	0	1	4	3	3	1	4	7	8	7	8	4	5	1	2	0	59	0.3
C12-C13	Hypopharynx	0	0	0	0	1	4	4	10	29	54	79	66	75	68	43	44	1	479	2.45
C14	Pharynx Unspecified	1	0	0	0	0	2	2	9	10	16	25	22	24	17	11	13	0	152	0.78
C15	Oesophagus	0	0	0	0	1	5	19	26	59	74	127	139	169	141	102	90	6	964	4.94
C16	Stomach	0	0	0	1	2	4	7	15	17	26	40	45	56	45	29	29	0	316	1.62
C17	Small Intestine	0	0	0	0	1	1	2	1	1	4	9	9	10	10	5	4	0	57	0.29
C18	Colon	0	1	0	1	9	7	14	13	33	44	54	68	75	80	43	50	0	492	2.52
C19-C20	Rectum	0	0	0	2	5	13	15	20	18	36	42	35	57	58	41	46	0	388	1.99
C21	Anus and Anal Canal	0	0	0	0	1	4	5	5	6	6	18	5	13	11	7	10	1	93	0.48
C22	Liver	2	1	2	0	0	1	4	8	6	23	25	46	49	75	36	37	1	317	1.62
C23-C24	Gallbladder etc.	0	0	0	0	4	2	8	11	17	29	44	38	40	35	25	28	0	281	1.44
C25	Pancreas	0	0	0	1	2	0	2	2	12	20	17	24	35	37	18	13	0	183	0.94
C30-C31	Nose, Sinuses etc.	0	0	0	4	1	3	1	6	9	13	16	6	6	6	6	8	0	85	0.44
C32	Larynx	0	0	0	0	1	3	7	14	25	39	74	88	111	72	55	55	0	544	2.79
C33-C34	Lung etc.	0	0	0	0	3	13	11	20	37	87	171	217	311	267	186	183	3	1512	7.75
C37-C38	Other Thoracic Organs	0	0	1	1	1	3	0	4	7	3	15	15	14	11	14	10	1	101	0.52
C40-C41	Bone	2	3	10	29	27	8	7	9	18	9	9	8	14	11	6	9	0	179	0.92
C43	Melanoma of Skin	0	0	0	1	0	3	9	10	7	8	11	13	20	15	22	15	0	134	0.69
C44	Other Skin	0	1	0	0	0	0	3	4	2	5	6	5	5	5	3	7	0	46	0.24
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	3	0.02
C47+C49	Conn. and Soft Tissue	4	6	4	4	9	9	5	7	9	9	11	8	7	12	7	9	0	120	0.61
C50	Breast	0	0	1	1	1	2	4	7	21	18	16	16	22	21	8	19	1	159	0.81
C60	Penis	0	1	0	0	1	4	3	9	9	5	11	17	22	18	8	14	0	122	0.62
C61	Prostate	0	0	0	1	0	2	0	4	2	10	26	85	134	193	188	257	2	906	4.64
C62	Testis	3	1	2	4	15	13	16	16	10	6	6	4	3	3	2	1	0	105	0.54
C63	Other Male Genital	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	4	0.02
C64	Kidney etc.	9	2	0	4	3	1	5	7	13	23	41	44	41	32	27	18	0	270	1.38
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	3	0.02
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	2	0	6	0.03
C67	Urinary Bladder	0	1	1	0	1	4	3	5	13	15	35	35	46	50	33	51	1	295	1.51
C68	Uns. Urinary Organs	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2	0	4	0.02
C69	Eye	2	1	0	0	1	0	1	2	3	1	2	5	1	2	1	1	0	23	0.12
C70-C72	Brain, Nervous System	5	15	10	14	14	16	18	39	35	35	37	25	34	21	12	11	0	341	1.75
C73	Thyroid	0	1	1	2	2	10	8	10	6	7	5	8	13	6	3	6	0	88	0.45
C74	Adrenal Gland	5	1	0	0	0	1	0	0	0	2	2	6	0	1	0	0	0	18	0.09
C81	Hodgkins Disease	2	9	11	13	15	11	8	5	7	4	12	18	6	4	6	4	0	135	0.69
C82-C85	NHL	5	14	11	23	26	22	22	30	31	34	65	51	71	76	63	47	0	591	3.03
C90	Multiple Myeloma	0	0	0	0	0	3	0	4	7	13	34	28	37	35	24	23	0	208	1.07
C91	Lymphoid Leuk.	50	45	32	38	29	20	23	17	21	17	19	29	50	25	34	29	0	478	2.45
C92-C94	Myeloid Leukaemia	12	15	7	13	22	28	41	46	33	45	41	44	39	43	19	15	1	465	2.38
C95	Leukaemia Uns	3	1	0	3	1	0	1	0	3	1	3	2	3	1	2	0	2	28	0.14
C96	CMD,O and U LHM	1	0	0	1	0	0	1	0	1	0	2	2	1	1	1	3	0	14	0.07
O&U*	Other and Uns	4	3	2	13	6	17	23	50	80	86	121	129	189	131	87	83	2	1028	5.27
	Total	113	124	98	185	247	380	737	1291	1691	1978	2408	2390	2659	2185	1501	1464	35	19486	100

*O&U includes the Sites (ICD-10: C26, C39, C48, C75, C76, C77, C78, C79, C80, C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number of incident Cancers by Five Year Age Group and Site (ICD-10) 2015-20 Females

%= Relative Proportion of Cancers of All Sites

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total	Percentage
C00	Lip	0	0	0	1	0	2	1	3	2	2	3	4	7	4	1	4	0	34	0.22
C01-C02	Tongue	0	0	1	2	3	14	29	43	84	91	98	90	86	60	47	30	0	678	4.38
C03-C06	Mouth	0	0	0	1	2	18	35	68	98	119	144	94	131	74	50	54	4	896	5.79
C07-C08	Salivary Gland	0	0	0	1	2	2	6	3	5	2	8	4	1	1	5	4	0	44	0.28
C09	Tonsil	0	0	0	2	0	0	1	2	1	2	2	4	4	5	3	3	0	29	0.19
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	3	2	4	2	3	0	2	1	0	17	0.11
C11	Nasopharynx	1	1	2	1	0	1	1	1	3	4	1	2	6	2	1	1	0	28	0.18
C12-C13	Hypopharynx	0	0	0	0	0	2	4	8	11	13	22	19	12	13	12	11	0	127	0.82
C14	Pharynx Unspecified	0	1	0	0	0	0	1	1	4	2	2	3	4	5	1	1	0	25	0.16
C15	Oesophagus	0	0	0	0	4	7	8	18	49	47	69	74	76	56	42	53	0	503	3.25
C16	Stomach	0	0	0	0	1	4	4	14	14	22	32	27	28	17	17	17	1	199	1.29
C17	Small Intestine	0	0	0	1	1	1	0	2	3	2	2	7	5	9	3	4	0	40	0.26
C18	Colon	0	0	1	2	3	1	7	13	25	30	20	32	32	42	24	23	0	255	1.65
C19-C20	Rectum	0	0	1	0	4	15	11	16	14	23	19	19	29	25	22	23	1	223	1.44
C21	Anus and Anal Canal	0	0	0	1	1	1	1	3	2	1	8	4	7	7	3	3	0	42	0.27
C22	Liver	2	0	0	0	3	2	2	3	6	13	11	19	19	9	12	13	0	114	0.74
C23-C24	Gallbladder etc.	0	0	0	1	4	12	17	21	26	62	45	51	47	39	17	26	0	368	2.38
C25	Pancreas	0	0	0	0	0	0	1	5	3	10	18	17	23	19	11	10	0	117	0.76
C30-C31	Nose, Sinuses etc.	0	1	0	1	0	2	1	2	5	3	3	8	6	5	2	5	0	44	0.28
C32	Larynx	0	0	0	0	1	0	1	2	6	7	6	11	10	8	6	9	0	67	0.43
C33-C34	Lung etc.	0	0	0	2	3	7	16	20	28	43	47	49	65	67	38	60	0	445	2.88
C37-C38	Other Thoracic Organs	0	0	0	0	0	1	1	4	1	6	6	6	4	5	3	4	0	41	0.27
C40-C41	Bone	0	2	7	22	4	5	10	5	11	12	10	14	8	2	4	6	1	124	0.8
C43	Melanoma of Skin	0	1	0	0	3	4	9	5	5	11	12	14	15	17	22	19	1	139	0.9
C44	Other Skin	0	0	1	0	0	1	0	2	3	3	1	4	4	3	3	13	0	38	0.25
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.01
C47+C49	Conn. and Soft Tissue	3	2	3	3	6	4	8	6	4	13	17	6	7	7	4	4	0	97	0.63
C50	Breast	0	0	1	24	38	83	238	388	559	765	785	702	647	519	314	284	8	5363	34.68
C51	Vulva	1	0	0	0	0	0	0	3	2	5	8	7	16	16	9	18	0	85	0.55
C52	Vagina	0	0	0	0	0	0	4	13	15	24	18	18	22	17	18	12	0	161	1.04
C53	Cervix Uteri	0	0	2	0	6	9	24	80	170	182	212	144	169	97	66	44	0	1205	7.79
C54	Corpus Uteri	0	0	0	0	0	6	8	11	25	54	62	81	95	71	37	30	0	480	3.1
C55	Uterus Unspecified	0	0	0	0	1	3	10	14	31	26	18	7	10	3	2	2	0	127	0.82
C56	Ovary etc.	0	1	5	11	23	25	38	35	77	98	129	112	120	71	39	34	3	824	5.33
C57	Other Female Genital	0	0	0	0	0	1	3	2	1	0	5	2	3	1	3	4	0	25	0.16
C58	Placenta	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	2	0.01
C64	Kidney etc.	8	1	0	1	2	4	3	7	11	11	17	17	23	22	11	13	0	151	0.98
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.01
C67	Urinary Bladder	0	0	0	1	2	0	2	5	3	6	7	9	18	16	9	11	0	89	0.58
C68	Uns. Urinary Organs	0	0	0	0	0	0	0	0	0	1	2	0	2	1	1	0	0	7	0.05
C69	Eye	9	2	0	0	1	0	0	0	0	1	1	2	1	2	1	2	0	22	0.14
C70-C72	Brain, Nervous System	6	10	9	7	9	13	23	25	19	26	17	14	26	17	3	2	0	226	1.46
C73	Thyroid	0	0	3	4	14	21	24	28	35	22	20	12	16	10	9	13	0	231	1.49
C74	Adrenal Gland	2	1	0	0	0	0	0	1	2	2	1	1	0	0	0	0	0	10	0.06
C81	Hodgkins Disease	1	1	5	4	11	10	5	4	4	3	7	8	9	1	2	3	0	78	0.5
C82-C85	NHL	1	3	3	7	8	11	16	27	24	39	41	46	51	42	23	37	1	381	2.46
C90	Multiple Myeloma	0	1	0	0	1	1	0	2	4	14	17	24	26	23	21	12	1	148	0.96
C91	Lymphoid Leuk.	20	27	24	13	4	7	13	16	5	14	11	15	18	16	19	12	0	234	1.51
C92-C94	Myeloid Leukaemia	3	4	4	5	18	22	25	25	30	37	20	22	25	23	17	11	0	291	1.88
C95	Leukaemia Uns	0	2	0	0	2	1	2	0	1	1	1	1	1	2	4	1	0	19	0.12
C96	CMD,O and U LHM	0	0	0	0	0	1	1	0	1	2	1	2	2	2	1	1	0	14	0.09
O&U*	Other and Uns	3	2	2	4	6	13	21	28	47	64	65	66	79	58	49	49	0	556	3.6
	Total	60	63	74	122	192	337	635	985	1482	1942	2075	1897	2018	1532	1013	996	21	15444	100

*O&U includes the Sites (ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and truncated (35-64 yrs) (TR) Incidence Rate per 100,000 population: 2015-20 – Males

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0	0	0	0.1	0	0.1	0.2	0.7	1.9	1.7	1.8	3	3	3.6	3	3	0.8	0.85	1.9
C01-C02	Tongue	0	0.1	0.1	0.2	0.7	2.1	8.7	16.2	22.6	23.4	27.4	27.2	35.1	38.3	31.8	18	10.6	10.51	24.5
C03-C06	Mouth	0.1	0.1	0.1	0.1	0.9	3.9	13.9	33.8	48.7	57.2	60.3	60.6	69.2	72	60.1	35.7	22.2	21.92	53.5
C07-C08	Salivary Gland	0	0	0	0	0.1	0.2	0.1	0.2	0.3	0.4	0.8	1	1.7	0.7	3	1.1	0.3	0.33	0.6
C09	Tonsil	0	0	0	0	0.1	0	0.2	0.6	1.3	2	2.9	3.4	5.3	4.3	4.9	1.4	1	1.01	2.4
C10	Other Oropharynx	0	0	0	0	0	0	0.2	0.5	0.7	1.2	1.8	2.7	3.3	3.9	3	2.7	0.7	0.71	1.5
C11	Nasopharynx	0.1	0	0.1	0.2	0.1	0.1	0.1	0.2	0.5	0.6	0.6	0.8	0.6	1.1	0.3	0.5	0.3	0.27	0.5
C12-C13	Hypopharynx	0	0	0	0	0	0.2	0.2	0.6	2.1	4.1	6.6	6.6	10.4	15.5	14.1	12.3	2.2	2.44	4.6
C14	Pharynx Unspecified	0.1	0	0	0	0	0.1	0.1	0.6	0.7	1.2	2.1	2.2	3.3	3.9	3.6	3.5	0.7	0.76	1.5
C15	Oesophagus	0	0	0	0	0	0.2	1	1.6	4.2	5.6	10.7	14	23.4	32.1	33.5	26.1	4.4	4.95	8.8
C16	Stomach	0	0	0	0.1	0.1	0.2	0.4	0.9	1.2	2	3.4	4.5	7.8	10.3	9.5	7.9	1.5	1.61	2.9
C17	Small Intestine	0	0	0	0	0	0	0.1	0.1	0.1	0.3	0.8	0.9	1.4	2.3	1.6	1.1	0.3	0.29	0.5
C18	Colon	0	0.1	0	0.1	0.4	0.3	0.7	0.8	2.3	3.3	4.5	6.8	10.4	18.2	14.1	13.6	2.3	2.52	4.2
C19-C20	Rectum	0	0	0	0.1	0.2	0.6	0.8	1.2	1.3	2.7	3.5	3.5	7.9	13.2	13.5	12.5	1.8	1.99	3.1
C21	Anus & Anal Canal	0	0	0	0	0	0.2	0.3	0.3	0.4	0.5	1.5	0.5	1.8	2.5	2.3	3	0.4	0.45	0.8
C22	Liver	0.1	0.1	0.1	0	0	0	0.2	0.5	0.4	1.7	2.1	4.6	6.8	17.1	11.8	10.3	1.5	1.72	2.3
C23-C24	Gallbladder	0	0	0	0	0.2	0.1	0.4	0.7	1.2	2.2	3.7	3.8	5.5	8	8.2	7.6	1.3	1.41	2.6
C25	Pancreas	0	0	0	0.1	0.1	0	0.1	0.1	0.8	1.5	1.4	2.4	4.9	8.4	5.9	3.5	0.8	0.97	1.6
C30-C31	Nose, Sinuses	0	0	0	0.2	0	0.1	0.1	0.4	0.6	1	1.3	0.6	0.8	1.4	2	2.2	0.4	0.4	0.8
C32	Larynx	0	0	0	0	0	0.1	0.4	0.9	1.8	2.9	6.2	8.9	15.4	16.4	18.1	15	2.5	2.81	5.2
C33-C34	Lung	0	0	0	0	0.1	0.6	0.6	1.2	2.6	6.5	14.4	21.8	43.1	60.8	61.1	50.7	7	8.1	12.7
C37-C38	Other Thoracic Organs	0	0	0.1	0.1	0	0.1	0	0.2	0.5	0.2	1.3	1.5	1.9	2.5	4.6	3	0.5	0.51	0.8
C40-C41	Bone	0.1	0.2	0.5	1.5	1.3	0.4	0.4	0.6	1.3	0.7	0.8	0.8	1.9	2.5	2	2.5	0.8	0.83	1
C43	Melanoma of Skin	0	0	0	0.1	0	0.1	0.5	0.6	0.5	0.6	0.9	1.3	2.8	3.4	7.2	4.1	0.6	0.69	1
C44	Other Skin	0	0.1	0	0	0	0	0.2	0.2	0.1	0.4	0.5	0.5	0.7	1.1	1	1.9	0.2	0.23	0.4
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.2	0.3	0	0	0.02	0
C47+C49	Conn. & Soft Tissue	0.2	0.3	0.2	0.2	0.4	0.4	0.3	0.4	0.6	0.7	0.9	0.8	1	2.7	2.3	2.5	0.6	0.58	0.7
C50	Breast	0	0	0.1	0.1	0	0.1	0.2	0.4	1.5	1.4	1.3	1.6	3	4.8	2.6	5.4	0.7	0.79	1.5
C60	Penis	0	0.1	0	0	0	0.2	0.2	0.6	0.6	0.4	0.9	1.7	3	4.1	2.6	3.8	0.6	0.62	1.1
C61	Prostate	0	0	0	0.1	0	0.1	0	0.2	0.1	0.8	2.2	8.6	18.6	44	61.7	70.5	4.2	5.24	4.1
C62	Testis	0.2	0.1	0.1	0.2	0.7	0.6	0.9	1	0.7	0.5	0.5	0.4	0.4	0.7	0.7	0.3	0.5	0.44	0.6
C63	Other Male Genital	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0.1	0.2	0	0	0	0.02	0
C64	Kidney etc.	0.6	0.1	0	0.2	0.1	0	0.3	0.4	0.9	1.7	3.4	4.4	5.7	7.3	8.9	4.9	1.2	1.38	2.5
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0.5	0	0.01	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0.2	0.3	0	0	0.5	0	0.03	0.1
C67	Bladder	0	0.1	0.1	0	0	0.2	0.2	0.3	0.9	1.1	2.9	3.5	6.4	11.4	10.8	14.2	1.4	1.57	2.2
C68	Uns. Urinary Organs	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0.5	0	0.02	0
C69	Eye	0.1	0.1	0	0	0	0	0.1	0.1	0.2	0.1	0.2	0.5	0.1	0.5	0.3	0.3	0.1	0.11	0.2
C70-C72	Brain, Nervous System	0.3	0.9	0.5	0.7	0.7	0.7	1	2.4	2.5	2.6	3.1	2.5	4.7	4.8	3.9	3	1.6	1.58	2.9
C73	Thyroid	0	0.1	0.1	0.1	0.1	0.5	0.4	0.6	0.4	0.5	0.4	0.8	1.8	1.4	1	1.6	0.4	0.4	0.7
C74	Adrenal Gland	0.3	0.1	0	0	0	0	0	0	0	0.2	0.2	0.6	0	0.2	0	0	0.1	0.09	0.1
C81	Hodgkin Disease	0.1	0.5	0.6	0.7	0.7	0.5	0.4	0.3	0.5	0.3	1	1.8	0.8	0.9	2	1.1	0.6	0.61	0.7
C82-C85	NHL	0.3	0.8	0.6	1.2	1.2	1	1.2	1.9	2.2	2.6	5.5	5.1	9.8	17.3	20.7	12.8	2.7	2.99	4.1
C90	Multiple Myeloma	0	0	0	0	0	0.1	0	0.2	0.5	1	2.9	2.8	5.1	8	7.9	6.3	1	1.1	1.8
C91	Lymphoid Leuk.	3.1	2.6	1.7	1.9	1.4	0.9	1.2	1.1	1.5	1.3	1.6	2.9	6.9	5.7	11.2	7.9	2.2	2.47	2.3
C92-C94	Myeloid Leukaemia	0.7	0.9	0.4	0.7	1	1.3	2.2	2.8	2.3	3.4	3.4	4.4	5.4	9.8	6.2	4.4	2.1	2.17	3.5
C95	Leukaemia Uns	0.2	0.1	0	0.2	0	0	0.1	0	0.2	0.1	0.3	0.2	0.4	0.2	0.7	0.5	0.1	0.13	0.2
C96	CMD, O&U LHM	0.1	0	0	0.1	0	0	0.1	0	0.1	0	0.2	0.2	0.1	0.2	0.3	0.8	0.1	0.07	0.1
O&U*	Other and Uns	0.2	0.2	0.1	0.7	0.3	0.8	1.2	3.1	5.7	6.5	10.2	13	26.2	29.8	28.6	23.2	4.7	5.2	9.6
All Sites	All Sites	7	7.1	5.3	9.5	11.7	17.6	39.3	79.8	119.7	148.9	202.6	240.6	368.6	497.9	492.8	408.3	89.8	95.94	178.7

*O&U includes the Sites (ICD-10: C26, C39, C48, C75, C76, C77, C78, C79, C80, C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and truncated (35-64 yrs) (TR) Incidence Rate per 100,000 population: 2015-20 – Females

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0	0	0	0.1	0	0.1	0.1	0.2	0.1	0.2	0.3	0.5	1.1	1	0.3	0.9	0.2	0.18	0.3
C01-C02	Tongue	0	0	0.1	0.1	0.2	0.7	1.6	2.9	6	6.8	8.9	10.2	13.2	14.6	14.8	7	3.4	3.38	7.5
C03-C06	Mouth	0	0	0	0.1	0.1	0.9	2	4.5	7	8.9	13	10.6	20.1	18	15.8	13.6	4.5	4.44	10
C07-C08	Salivary Gland	0	0	0	0.1	0.1	0.1	0.3	0.2	0.4	0.2	0.7	0.5	0.2	0.2	1.6	0.9	0.2	0.2	0.3
C09	Tonsil	0	0	0	0.1	0	0	0.1	0.1	0.1	0.2	0.2	0.5	0.6	1.2	0.9	0.7	0.1	0.16	0.2
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0.2	0.2	0.4	0.2	0.5	0	0.6	0.2	0.1	0.08	0.2
C11	Nasopharynx	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0.2	0.3	0.1	0.2	0.9	0.5	0.3	0.2	0.1	0.15	0.3
C12-C13	Hypopharynx	0	0	0	0	0	0.1	0.2	0.5	0.8	1	2	2.2	1.8	3.2	3.8	2.6	0.6	0.64	1.3
C14	Pharynx Unspecified	0	0.1	0	0	0	0	0.1	0.1	0.3	0.2	0.2	0.3	0.6	1.2	0.3	0.2	0.1	0.14	0.2
C15	Oesophagus	0	0	0	0	0.2	0.3	0.5	1.2	3.5	3.5	6.2	8.4	11.7	13.6	13.3	12.4	2.6	2.6	5.2
C16	Stomach	0	0	0	0	0.1	0.2	0.2	0.9	1	1.7	2.9	3.1	4.3	4.1	5.4	4.2	1	1	2.1
C17	Small Intestine	0	0	0	0.1	0.1	0	0	0.1	0.2	0.2	0.2	0.8	0.8	2.2	0.9	0.9	0.2	0.22	0.3
C18	Colon	0	0	0.1	0.1	0.2	0	0.4	0.9	1.8	2.3	1.8	3.6	4.9	10.2	7.6	5.4	1.3	1.35	2.3
C19-C20	Rectum	0	0	0.1	0	0.2	0.7	0.6	1.1	1	1.7	1.7	2.2	4.5	6.1	6.9	5.6	1.1	1.13	1.9
C21	Anus & Anal Canal	0	0	0	0.1	0.1	0	0.1	0.2	0.1	0.1	0.7	0.5	1.1	1.7	0.9	0.7	0.2	0.22	0.4
C22	Liver	0.1	0	0	0	0.2	0.1	0.1	0.2	0.4	1	1	2.2	2.9	2.2	3.8	3	0.6	0.59	1.1
C23-C24	Gallbladder	0	0	0	0.1	0.2	0.6	1	1.4	1.9	4.7	4.1	5.8	7.2	9.5	5.4	6.1	1.9	1.84	3.9
C25	Pancreas	0	0	0	0	0	0	0.1	0.3	0.2	0.8	1.6	1.9	3.5	4.6	3.5	2.3	0.6	0.64	1.2
C30-C31	Nose, Sinuses	0	0.1	0	0.1	0	0.1	0.1	0.1	0.4	0.2	0.3	0.9	0.9	1.2	0.6	1.2	0.2	0.23	0.4
C32	Larynx	0	0	0	0	0.1	0	0.1	0.1	0.4	0.5	0.5	1.2	1.5	1.9	1.9	2.1	0.3	0.35	0.7
C33-C34	Lung	0	0	0	0.1	0.2	0.3	0.9	1.3	2	3.2	4.2	5.5	10	16.3	12	14.1	2.3	2.34	4
C37-C38	Other Thoracic Organs	0	0	0	0	0	0	0.1	0.3	0.1	0.5	0.5	0.7	0.6	1.2	0.9	0.9	0.2	0.21	0.4
C40-C41	Bone	0	0.1	0.5	1.4	0.2	0.2	0.6	0.3	0.8	0.9	0.9	1.6	1.2	0.5	1.3	1.6	0.6	0.61	0.9
C43	Melanoma of Skin	0	0.1	0	0	0.2	0.2	0.5	0.3	0.4	0.8	1.1	1.6	2.3	4.1	6.9	4.7	0.7	0.72	1
C44	Other Skin	0	0	0.1	0	0	0	0	0.1	0.2	0.2	0.1	0.5	0.6	0.7	0.9	3	0.2	0.19	0.3
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0
C47+C49	Conn. & Soft Tissue	0.2	0.1	0.2	0.2	0.3	0.2	0.5	0.4	0.3	1	1.5	0.7	1.1	1.7	1.3	0.9	0.5	0.48	0.8
C50	Breast	0	0	0.1	1.5	1.9	4.1	13.5	25.8	40.2	57.4	71	79.5	99.3	126.5	99.1	68.5	27.2	26.69	58.4
C51	Vulva	0.1	0	0	0	0	0	0	0.2	0.1	0.4	0.7	0.8	2.5	3.9	2.8	4.2	0.4	0.48	0.7
C52	Vagina	0	0	0	0	0	0	0.2	0.9	1.1	1.8	1.6	2	3.4	4.1	5.7	2.8	0.8	0.83	1.7
C53	Cervix Uteri	0	0	0.1	0	0.3	0.4	1.4	5.3	12.2	13.7	19.2	16.3	26	23.6	20.8	10.3	6.1	6.01	14.6
C54	Corpus Uteri	0	0	0	0	0	0.3	0.5	0.7	1.8	4.1	5.6	9.2	14.6	17.3	11.7	7	2.4	2.57	5.2
C55	Uterus Unspecified	0	0	0	0	0.1	0.1	0.6	0.9	2.2	2	1.6	0.8	1.5	0.7	0.6	0.5	0.6	0.58	1.6
C56	Ovary etc.	0	0.1	0.3	0.7	1.2	1.2	2.2	2.3	5.5	7.4	11.7	12.7	18.4	17.3	12.3	8.7	4.2	4.1	8.8
C57	Other Female Genital	0	0	0	0	0	0	0.2	0.1	0.1	0	0.5	0.2	0.5	0.2	0.9	0.9	0.1	0.12	0.2
C58	C58	0	0	0	0	0.1	0	0	0.1	0	0	0	0	0	0	0	0	0	0.01	0
C64	Kidney etc.	0.6	0.1	0	0.1	0.1	0.2	0.2	0.5	0.8	0.8	1.5	1.9	3.5	5.4	3.5	3	0.8	0.82	1.4
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.01	0
C67	Bladder	0	0	0	0.1	0.1	0	0.1	0.3	0.2	0.5	0.6	1	2.8	3.9	2.8	2.6	0.5	0.49	0.8
C68	Uns. Urinary Organs	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0.3	0.2	0.3	0	0	0.04	0.1
C69	Eye	0.6	0.1	0	0	0.1	0	0	0	0	0.1	0.1	0.2	0.2	0.5	0.3	0.5	0.1	0.15	0.1
C70-C72	Brain, Nervous System	0.4	0.7	0.6	0.4	0.5	0.6	1.3	1.7	1.4	2	1.5	1.6	4	4.1	0.9	0.5	1.1	1.13	1.9
C73	Thyroid	0	0	0.2	0.3	0.7	1	1.4	1.9	2.5	1.7	1.8	1.4	2.5	2.4	2.8	3	1.2	1.06	2
C74	Adrenal Gland	0.1	0.1	0	0	0	0	0	0.1	0.1	0.2	0.1	0.1	0	0	0	0	0.1	0.05	0.1
C81	Hodgkin Disease	0.1	0.1	0.3	0.3	0.6	0.5	0.3	0.3	0.3	0.2	0.6	0.9	1.4	0.2	0.6	0.7	0.4	0.37	0.5
C82-C85	NHL	0.1	0.2	0.2	0.4	0.4	0.5	0.9	1.8	1.7	2.9	3.7	5.2	7.8	10.2	7.3	8.9	1.9	1.94	3.5
C90	Multiple Myeloma	0	0.1	0	0	0	0	0	0.1	0.3	1.1	1.5	2.7	4	5.6	6.6	3	0.7	0.81	1.4
C91	Lymphoid Leuk.	1.4	1.9	1.6	0.8	0.2	0.3	0.7	1.1	0.4	1.1	1	1.7	2.8	3.9	6	2.8	1.2	1.34	1.2
C92-C94	Myeloid Leukaemia	0.2	0.3	0.3	0.3	0.9	1.1	1.4	1.7	2.2	2.8	1.8	2.5	3.8	5.6	5.4	2.6	1.5	1.42	2.4
C95	Leukaemia Uns	0	0.1	0	0	0.1	0	0.1	0	0.1	0.1	0.1	0.1	0.2	0.5	1.3	0.2	0.1	0.1	0.1
C96	CMD, O&U LHM	0	0	0	0	0	0	0.1	0	0.1	0.2	0.1	0.2	0.3	0.5	0.3	0.2	0.1	0.07	0.1
O&U*	Other and Uns	0.2	0.1	0.1	0.3	0.3	0.6	1.2	1.9	3.4	4.8	5.9	7.5	12.1	14.1	15.5	11.5	2.8	2.87	5.4
All Sites	All Sites	4.2	4.5	5.1	7.8	9.7	16.5	36.1	65.4	106.6	145.8	187.6	214.8	309.9	373.3	319.8	238.5	78.5	78.17	159.5

*O&U includes the Sites (ICD-10: C26, C39, C48, C75, C76, C77, C78, C79, C80, C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number of Cancer Deaths by Five Year Age Group and Site(ICD-10) 2015-2020 - Males

Relative proportion of Cancers of All sites

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total	Percentage
C00	Lip	0	0	0	0	0	0	0	3	6	7	5	10	9	2	1	6	0	49	0.62
C01-C02	Tongue	0	0	0	0	6	19	66	102	129	154	170	152	135	96	54	48	0	1131	14.37
C03-C06	Mouth	0	0	0	0	12	25	94	223	276	292	280	238	219	138	78	75	0	1950	24.77
C07-C08	Salivary Gland	0	0	0	0	0	1	1	0	0	1	5	2	3	0	2	2	0	17	0.22
C09	Tonsil	0	0	0	0	0	0	1	6	14	14	28	20	36	18	7	11	0	155	1.97
C10	Oth. Oropharynx	0	0	0	0	0	0	0	3	1	7	11	19	15	8	6	4	0	74	0.94
C11	Nasopharynx	0	0	0	1	1	2	0	2	4	4	4	7	1	6	1	1	0	34	0.43
C12-C13	Hypopharynx	0	0	0	0	1	1	1	7	18	46	47	34	49	49	34	44	0	331	4.20
C14	Pharynx Unspecified	0	0	0	0	0	1	0	9	5	13	19	15	18	19	6	14	0	119	1.51
C15	Oesophagus	0	0	0	0	1	1	7	14	31	39	57	72	78	74	45	47	0	466	5.92
C16	Stomach	0	0	0	0	0	1	2	3	9	9	15	16	18	16	13	14	0	116	1.47
C17	Small Intestine	0	0	0	0	0	0	0	0	1	1	2	2	3	3	1	1	0	14	0.18
C18	Colon	0	0	0	0	4	1	4	2	6	12	10	13	16	13	12	12	0	105	1.33
C19-C20	Rectum	0	0	0	2	2	3	4	9	6	11	17	12	19	12	8	12	0	117	1.49
C21	Anus and Anal Canal	0	0	0	0	0	1	3	1	1	4	7	1	5	1	3	3	0	30	0.38
C22	Liver	1	1	0	0	0	0	0	3	2	11	11	20	17	23	12	21	0	122	1.55
C23-C24	Gallbladder etc.	0	0	0	0	0	0	1	4	8	6	15	16	18	5	12	12	0	97	1.23
C25	Pancreas	0	0	0	0	0	0	1	1	5	10	6	10	8	15	7	7	0	70	0.89
C30-C31	Nose, Sinuses etc.	0	0	0	2	1	1	1	1	7	7	1	2	3	1	2	1	0	30	0.38
C32	Larynx	0	0	0	0	0	2	4	5	16	15	44	47	68	41	37	35	0	314	3.99
C33-C34	Lung etc.	0	0	0	0	1	5	5	8	13	47	85	95	139	119	87	60	0	664	8.43
C37-C38	Other Thoracic Organs	0	0	0	1	1	0	0	1	5	2	6	8	6	5	2	1	0	38	0.48
C40-C41	Bone	1	2	4	16	8	0	1	2	0	2	2	5	4	0	1	0	0	50	0.64
C43	Melanoma of Skin	0	0	0	0	0	1	1	4	2	1	8	3	1	5	2	6	0	34	0.43
C44	Other Skin	0	0	0	0	0	0	0	3	1	1	1	4	3	1	3	4	0	21	0.27
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.01
C47+C49	Conn. and Soft Tissue	3	5	3	1	2	4	0	3	4	1	4	5	2	9	5	1	0	52	0.66
C50	Breast	0	0	0	0	0	1	0	1	3	6	2	3	5	9	4	2	0	36	0.46
C60	Penis	0	0	0	0	0	0	3	2	1	2	4	5	8	5	6	9	0	45	0.57
C61	Prostate	0	0	0	0	0	0	0	2	0	2	5	15	28	28	38	66	0	184	2.34
C62	Testis	0	0	0	0	0	4	1	3	0	5	2	2	2	1	0	0	0	20	0.25
C63	Other Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.01
C64	Kidney etc.	3	1	0	0	3	0	2	2	3	7	11	15	13	14	9	5	0	88	1.12
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C67	Urinary Bladder	0	0	0	0	1	1	0	1	0	3	7	6	18	20	14	19	0	90	1.14
C68	Uns. Urinary Organs	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	2	0.03
C69	Eye	2	0	0	0	0	0	0	1	1	0	1	1	0	0	0	0	0	6	0.08
C70-C72	Brain, Nervous System	2	4	3	2	8	4	9	14	11	15	16	10	10	11	5	4	0	128	1.63
C73	Thyroid	0	0	0	0	0	0	1	1	1	2	3	2	4	0	0	0	0	14	0.18
C74	Adrenal Gland	2	0	0	0	0	0	0	0	1	0	1	4	0	0	0	0	0	8	0.10
C81	Hodgkins Disease	0	0	1	0	2	3	0	0	2	3	4	2	1	2	3	1	0	24	0.30
C82-C85	NHL	1	5	4	4	11	7	7	4	8	11	16	16	18	19	19	16	0	166	2.11
C90	Multiple Myeloma	0	0	0	0	0	1	0	2	2	4	14	6	19	14	4	7	0	73	0.93
C91	Lymphoid Leuk.	11	13	14	17	6	9	8	5	6	3	7	10	8	10	14	5	0	146	1.85
C92-C94	Myeloid Leukaemia	5	9	4	7	5	5	20	21	13	15	17	26	16	20	6	3	0	192	2.44
C95	Leukaemia Uns	0	0	0	1	0	0	1	0	1	0	0	0	1	0	0	0	0	4	0.05
C96	CMD,O and U LHM	0	0	0	1	0	0	0	0	0	0	1	1	1	0	0	2	0	6	0.08
O&U*	Other and Uns	1	0	0	3	4	8	4	12	28	40	55	51	95	55	46	37	0	439	5.58
	Total	32	40	33	58	80	112	253	490	651	835	1027	1000	1142	892	609	619	0	7873	100.00

*O&U includes the Sites(ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number of Cancer Deaths by Five Year Age Group and Site(ICD-10) 2015-2020 - Females

Relative proportion of Cancers of All sites

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total	Percentage
C00	Lip	0	0	0	0	0	0	0	1	2	1	2	1	2	2	0	2	0	13	0.26
C01-C02	Tongue	0	0	0	1	2	7	12	23	30	40	37	41	41	25	22	18	0	299	5.94
C03-C06	Mouth	0	0	0	1	0	6	11	29	31	51	57	43	67	47	23	29	0	395	7.85
C07-C08	Salivary Gland	0	0	0	0	1	0	2	0	0	0	2	1	0	2	0	4	0	12	0.24
C09	Tonsil	0	0	0	0	0	0	0	0	0	2	1	1	4	3	2	3	0	16	0.32
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	1	1	0	3	4	0	1	0	0	10	0.20
C11	Nasopharynx	0	0	0	1	1	1	1	0	1	2	0	0	3	1	1	1	0	13	0.26
C12-C13	Hypopharynx	0	0	0	0	0	2	4	5	4	8	14	16	11	11	8	9	0	92	1.83
C14	Pharynx Unspecified	0	0	0	0	0	0	0	1	2	2	1	2	2	2	1	0	0	13	0.26
C15	Oesophagus	0	0	0	0	1	1	8	8	19	21	40	32	35	25	20	22	0	232	4.61
C16	Stomach	0	0	0	0	1	1	2	5	6	16	14	15	11	8	7	4	0	90	1.79
C17	Small Intestine	0	0	0	1	1	0	0	1	1	2	1	1	2	4	1	2	0	17	0.34
C18	Colon	0	0	0	1	0	0	1	3	5	8	4	12	8	8	2	6	0	58	1.15
C19-C20	Rectum	0	0	1	0	3	8	5	8	6	5	5	9	9	2	9	8	0	78	1.55
C21	Anus and Anal Canal	0	0	0	0	0	0	0	1	1	0	1	1	3	4	1	1	0	13	0.26
C22	Liver	3	0	0	0	2	1	1	2	1	4	4	8	3	2	2	4	0	37	0.74
C23-C24	Gallbladder etc.	0	0	0	0	0	3	5	8	11	30	20	20	20	15	5	10	0	147	2.92
C25	Pancreas	0	0	0	0	0	0	2	2	1	4	5	9	11	10	3	3	0	50	0.99
C30-C31	Nose, Sinuses etc.	0	0	0	1	0	0	1	0	0	1	2	2	2	4	1	2	0	16	0.32
C32	Larynx	0	0	0	0	0	0	0	0	0	1	4	6	6	8	2	4	0	31	0.62
C33-C34	Lung etc.	0	0	0	0	3	4	5	4	24	12	24	26	27	13	11	0	153	3.04	
C37-C38	Other Thoracic Organs	0	0	0	0	0	0	0	1	0	4	1	3	2	0	3	1	0	15	0.30
C40-C41	Bone	0	0	2	6	2	1	1	0	2	2	2	1	3	0	3	1	0	26	0.52
C43	Melanoma of Skin	0	0	0	0	0	0	1	1	0	2	1	5	2	6	5	4	0	27	0.54
C44	Other Skin	0	0	0	0	0	0	0	1	0	0	2	0	4	4	3	2	0	16	0.32
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.02
C47+C49	Conn. and Soft Tissue	1	0	0	2	1	1	5	1	0	4	5	3	4	3	4	3	0	37	0.74
C50	Breast	0	0	0	2	5	11	51	107	153	183	220	189	184	146	103	95	0	1449	28.78
C51	Vulva	0	0	0	0	0	0	0	1	2	1	1	4	5	5	2	10	0	31	0.62
C52	Vagina	0	0	0	0	0	0	0	1	2	3	6	2	6	6	9	5	0	40	0.79
C53	Cervix Uteri	0	0	1	0	1	1	10	25	71	69	78	64	69	50	36	35	0	510	10.13
C54	Corpus Uteri	0	0	0	0	0	0	1	0	2	7	9	17	23	12	10	10	0	91	1.81
C55	Uterus Unspecified	0	0	0	0	0	0	1	0	0	1	4	0	1	0	0	1	0	8	0.16
C56	Ovary etc.	0	1	1	1	2	1	4	6	11	34	34	36	37	23	18	13	0	222	4.41
C57	Other Female Genital	0	0	0	0	0	0	0	0	0	0	3	1	2	1	0	2	0	9	0.18
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64	Kidney etc.	2	1	0	0	0	0	0	2	2	3	1	12	4	8	2	4	0	41	0.81
C66	Ureter	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	2	0.04
C67	Urinary Bladder	0	0	0	0	0	0	1	0	1	2	3	1	7	6	3	4	0	28	0.56
C68	Uns. Urinary Organs	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0	4	0.08
C69	Eye	3	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	5	0.10
C70-C72	Brain, Nervous System	1	1	4	3	1	1	6	4	7	9	9	6	11	10	5	0	0	78	1.55
C73	Thyroid	0	0	0	0	0	0	0	2	2	3	5	3	8	2	2	3	0	30	0.60
C74	Adrenal Gland	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	3	0.06
C81	Hodgkins Disease	1	0	0	0	1	2	0	0	0	0	3	4	3	0	1	0	0	15	0.30
C82-C85	NHL	1	1	1	2	2	3	2	7	4	12	6	8	17	9	6	14	0	95	1.89
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	1	5	12	7	8	6	1	5	0	45	0.89
C91	Lymphoid Leuk.	5	8	8	4	1	2	5	5	3	11	3	3	6	1	3	1	0	69	1.37
C92-C94	Myeloid Leukaemia	5	4	4	0	2	9	7	8	15	14	11	10	9	9	8	5	0	120	2.38
C95	Leukaemia Uns	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0.04
C96	CMD,O and U LHM	0	0	0	0	0	1	0	0	0	0	1	1	2	0	0	0	0	5	0.10
O&U*	Other and Uns	1	0	1	1	2	4	5	10	18	28	26	34	33	18	22	22	0	225	4.47
	Total	23	19	23	27	32	70	159	285	423	621	673	662	721	536	377	383	0	5034	100

*O&U includes the Sites (ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and Truncated (35-64 yrs) (TR) Mortality Rate per 100,000 population :2015-2020 – Males

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CMR	AAMR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.5	0.4	1.0	1.2	0.5	0.3	1.6	0.2	0.2
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.3	0.9	3.5	6.3	9.1	11.6	14.3	15.3	18.7	21.9	17.7	13.1	5.2	5.3
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.6	1.2	5.0	13.8	19.5	22.0	23.6	24.0	30.4	31.4	25.6	20.4	9.0	9.0
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.4	0.2	0.4	0.0	0.7	0.5	0.1	0.1
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.0	1.1	2.4	2.0	5.0	4.1	2.3	3.0	0.7	0.8
C10	Other Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.5	0.9	1.9	2.1	1.8	2.0	1.1	0.3	0.4
C11	Nasopharynx	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.3	0.3	0.3	0.7	0.1	1.4	0.3	0.3	0.2	0.2
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.3	3.5	4.0	3.4	6.8	11.2	11.2	12.0	1.5	1.7
C14	Pharynx Unspecified	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.4	1.0	1.6	1.5	2.5	4.3	2.0	3.8	0.5	0.6
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.9	2.2	2.9	4.8	7.2	10.8	16.9	14.8	12.8	2.1	2.4
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.6	0.7	1.3	1.6	2.5	3.6	4.3	3.8	0.5	0.6
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.4	0.7	0.3	0.3	0.1	0.1
C18	Colon	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.4	0.9	0.8	1.3	2.2	3.0	3.9	3.3	0.5	0.5
C19-C20	Rectum	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.6	0.4	0.8	1.4	1.2	2.6	2.7	2.6	3.3	0.5	0.6
C21	Anus & Anal Canal	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.3	0.6	0.1	0.7	0.2	1.0	0.8	0.1	0.1
C22	Liver	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.8	0.9	2.0	2.4	5.2	3.9	5.7	0.6	0.7
C23-C24	Gallbladder	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.6	0.5	1.3	1.6	2.5	1.1	3.9	3.3	0.4	0.5
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.8	0.5	1.0	1.1	3.4	2.3	1.9	0.3	0.4
C30-C31	Nose, Sinuses	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.5	0.5	0.1	0.2	0.4	0.2	0.7	0.3	0.1	0.1
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	1.1	1.1	3.7	4.7	9.4	9.3	12.1	9.5	1.4	1.6
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.5	0.9	3.5	7.2	9.6	19.3	27.1	28.6	16.3	3.1	3.6
C37-C38	Other Thoracic Organs	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.4	0.2	0.5	0.8	0.8	1.1	0.7	0.3	0.2	0.2
C40-C41	Bone	0.1	0.1	0.2	0.8	0.4	0.0	0.1	0.1	0.0	0.2	0.2	0.2	0.7	0.9	0.0	0.3	0.2	0.2
C43	Melanoma of Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.1	0.7	0.3	0.1	1.1	0.7	1.6	0.2	0.2
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.4	0.4	0.2	1.0	1.1	0.1	0.1
C45	Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0
C47+C49	Conn. & Soft Tissue	0.2	0.3	0.2	0.1	0.1	0.2	0.0	0.2	0.3	0.1	0.3	0.5	0.3	2.1	1.6	0.3	0.2	0.3
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.2	0.3	0.7	2.1	1.3	0.5	0.2	0.2
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.2	0.3	0.5	1.1	1.1	2.0	2.5	0.2	0.2
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	1.5	3.9	6.4	12.5	18.0	0.8	1.1
C62	Testis	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.2	0.0	0.4	0.2	0.2	0.3	0.2	0.0	0.0	0.1	0.1
C63	Other Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
C64	Kidney etc.	0.2	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.2	0.5	0.9	1.5	1.8	3.2	3.0	1.4	0.4	0.5
C65	Renal Pelvis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.6	0.6	2.5	4.6	4.6	5.2	0.4	0.5
C68	Uns. Urinary Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain, Nervous System	0.1	0.2	0.2	0.1	0.4	0.2	0.5	0.9	0.8	1.1	1.3	1.0	1.4	2.5	1.6	1.1	0.6	0.6
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.2	0.6	0.0	0.0	0.0	0.1	0.1
C74	Adrenal Gland	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin Disease	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.2	0.3	0.2	0.1	0.5	1.0	0.3	0.1	0.1
C82-C85	NHL	0.1	0.3	0.2	0.2	0.5	0.3	0.4	0.2	0.6	0.8	1.3	1.6	2.5	4.3	6.2	4.4	0.8	0.8
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	1.2	0.6	2.6	3.2	1.3	1.9	0.3	0.4
C91	Lymphoid Leuk.	0.7	0.7	0.8	0.9	0.3	0.4	0.4	0.3	0.4	0.2	0.6	1.0	1.1	2.3	4.6	1.4	0.7	0.7
C92-C94	Myeloid Leukaemia	0.3	0.5	0.2	0.4	0.2	0.2	1.1	1.3	0.9	1.1	1.4	2.6	2.2	4.6	2.0	0.8	0.9	0.9
C95	Leukaemia Uns	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
C96	CMD, O&U LHM	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.5	0.0	0.0
O&U*	Other and Uns	0.1	0.0	0.0	0.2	0.2	0.4	0.2	0.7	2.0	3.0	4.6	5.1	13.2	12.5	15.1	10.1	2.0	2.3
All Sites	All Sites	2.0	2.3	1.8	3.0	3.8	5.2	13.5	30.3	46.1	62.9	86.4	100.7	158.3	203.2	199.9	168.6	36.3	38.9

*O&U includes the Sites(ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Average Annual Age Specific, Crude (CR), Age Adjusted (AAR) (With Standard Error (SE)) and Truncated (35-64 yrs) (TR) Mortality Rate per 100,000 population :2015-2020 – Females

ICD10	ICD10-Description	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CMR	AAMR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.3	0.5	0.0	0.5	0.1	0.1
C01-C02	Tongue	0.0	0.0	0.0	0.1	0.1	0.3	0.7	1.5	2.2	3.0	3.3	4.6	6.3	6.1	6.9	4.2	1.5	1.5
C03-C06	Mouth	0.0	0.0	0.0	0.1	0.0	0.3	0.6	1.9	2.2	3.8	5.2	4.9	10.3	11.5	7.3	6.8	2.0	2.0
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.5	0.0	0.9	0.1	0.1
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.6	0.7	0.6	0.7	0.1	0.1
C10	Other Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.6	0.0	0.3	0.0	0.1	0.1
C11	Nasopharynx	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.5	0.2	0.3	0.2	0.1	0.1
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.3	0.6	1.3	1.8	1.7	2.7	2.5	2.1	0.5	0.5
C14	Pharynx Unspecified	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.2	0.3	0.5	0.3	0.0	0.1	0.1
C15	Oesophagus	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.5	1.4	1.6	3.6	3.6	5.4	6.1	6.3	5.2	1.2	1.2
C16	Stomach	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.4	1.2	1.3	1.7	1.7	1.9	2.2	0.9	0.5	0.5
C17	Small Intestine	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.3	1.0	0.3	0.5	0.1	0.1
C18	Colon	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.4	0.6	0.4	1.4	1.2	1.9	0.6	1.4	0.3	0.3
C19-C20	Rectum	0.0	0.0	0.1	0.0	0.2	0.4	0.3	0.5	0.4	0.4	0.5	1.0	1.4	0.5	2.8	1.9	0.4	0.4
C21	Anus & Anal Canal	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.5	1.0	0.3	0.2	0.1	0.1
C22	Liver	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.3	0.4	0.9	0.5	0.5	0.6	0.9	0.2	0.2
C23-C24	Gallbladder	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.5	0.8	2.3	1.8	2.3	3.1	3.7	1.6	2.3	0.7	0.7
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.5	1.0	1.7	2.4	0.9	0.7	0.3	0.3
C30-C31	Nose, Sinuses	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.2	0.3	1.0	0.3	0.5	0.1	0.1
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.7	0.9	1.9	0.6	0.9	0.2	0.2
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.3	1.8	1.1	2.7	4.0	6.6	4.1	2.6	0.8	0.8
C37-C38	Other Thoracic Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.3	0.3	0.0	0.9	0.2	0.1	0.1
C40-C41	Bone	0.0	0.0	0.1	0.4	0.1	0.0	0.1	0.0	0.1	0.2	0.2	0.1	0.5	0.0	0.9	0.2	0.1	0.1
C43	Melanoma of Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.1	0.6	0.3	1.5	1.6	0.9	0.1	0.2
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.6	1.0	0.9	0.5	0.1	0.1
C45	Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
C47+C49	Conn. & Soft Tissue	0.1	0.0	0.0	0.1	0.1	0.0	0.3	0.1	0.0	0.3	0.5	0.3	0.6	0.7	1.3	0.7	0.2	0.2
C50	Breast	0.0	0.0	0.0	0.1	0.3	0.5	2.9	7.1	11.0	13.7	19.9	21.4	28.3	35.6	32.5	22.3	7.4	7.3
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.5	0.8	1.2	0.6	2.3	0.2	0.2
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.5	0.2	0.9	1.5	2.8	1.2	0.2	0.2
C53	Cervix Uteri	0.0	0.0	0.1	0.0	0.1	0.0	0.6	1.7	5.1	5.2	7.1	7.2	10.6	12.2	11.4	8.2	2.6	2.6
C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.5	0.8	1.9	3.5	2.9	3.2	2.3	0.5	0.5
C55	Uterus Unspecified	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.2	0.0	0.0
C56	Ovary etc.	0.0	0.1	0.1	0.1	0.1	0.0	0.2	0.4	0.8	2.6	3.1	4.1	5.7	5.6	5.7	3.0	1.1	1.2
C57	Other Female Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.3	0.2	0.0	0.5	0.0	0.0
C58	C58	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney etc.	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1	1.4	0.6	1.9	0.6	0.9	0.2	0.2
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
C67	Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.3	0.1	1.1	1.5	0.9	0.9	0.1	0.2
C68	Uns. Urinary Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.6	0.0	0.0	0.0
C69	Eye	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0
C70-C72	Brain, Nervous System	0.1	0.1	0.3	0.2	0.1	0.0	0.3	0.3	0.5	0.7	0.8	0.7	1.7	2.4	1.6	0.0	0.4	0.4
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.5	0.3	1.2	0.5	0.6	0.7	0.2	0.2
C74	Adrenal Gland	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin Disease	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.5	0.5	0.0	0.3	0.0	0.1	0.1
C82-C85	NHL	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.5	0.3	0.9	0.5	0.9	2.6	2.2	1.9	3.3	0.5	0.5
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.1	0.8	1.2	1.5	0.3	1.2	0.2	0.2
C91	Lymphoid Leuk.	0.3	0.6	0.5	0.3	0.1	0.1	0.3	0.3	0.2	0.8	0.3	0.3	0.9	0.2	0.9	0.2	0.4	0.4
C92-C94	Myeloid Leukaemia	0.3	0.3	0.3	0.0	0.1	0.4	0.4	0.5	1.1	1.1	1.0	1.1	1.4	2.2	2.5	1.2	0.6	0.6
C95	Leukaemia Uns	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0
C96	CMD, O&U LHM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0
O&U*	Other and Uns	0.1	0.0	0.1	0.1	0.1	0.2	0.3	0.7	1.3	2.1	2.4	3.9	5.1	4.4	6.9	5.2	1.1	1.2
All Sites	All Sites	1.6	1.4	1.6	1.7	1.6	3.4	9.0	18.9	30.4	46.6	60.9	75.0	110.7	130.6	119.0	89.8	25.6	25.9

*O&U includes the Sites (ICD-10: C26, C39, C48, C75, C76, C77, C78, C79, C80, C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number (#) and Proportion (%) of Cancers by site (ICD-10) and Method of Diagnosis:

2015-2020 Males

ICD10		Clinical		Microscopic		X-Ray Imaging		DCO		Others		Unknown		Total Count
Code	Description	n	%	n	%	n	%	n	%	n	%	n	%	N
C00	Lip	0	0	178	99.44	1	0.56	0	0	0	0	0	0	179
C01-C02	Tongue	4	0.17	2271	98.74	18	0.78	0	0	5	0.22	2	0.09	2300
C03-C06	Mouth	12	0.25	4750	98.71	38	0.79	1	0.02	8	0.17	3	0.06	4812
C07-C08	Salivary Gland	0	0	64	92.75	5	7.25	0	0	0	0	0	0	69
C09	Tonsil	0	0	206	99.52	1	0.48	0	0	0	0	0	0	207
C10	Oth. Oropharynx	0	0	137	94.48	6	4.14	0	0	2	1.38	0	0	145
C11	Nasopharynx	0	0	59	100	0	0	0	0	0	0	0	0	59
C12-C13	Hypopharynx	1	0.21	474	99.16	2	0.42	0	0	0	0	1	0.21	478
C14	Pharynx Unspecified	0	0	150	98.68	2	1.32	0	0	0	0	0	0	152
C15	Oesophagus	3	0.31	942	98.33	11	1.15	0	0	2	0.21	0	0	958
C16	Stomach	0	0	309	97.78	6	1.9	0	0	0	0	1	0.32	316
C17	Small Intestine	0	0	55	96.49	2	3.51	0	0	0	0	0	0	57
C18	Colon	1	0.2	482	97.97	6	1.22	0	0	3	0.61	0	0	492
C19-C20	Rectum	0	0	380	97.94	4	1.03	0	0	3	0.77	1	0.26	388
C21	Anus and Anal Canal	0	0	91	98.91	1	1.09	0	0	0	0	0	0	92
C22	Liver	1	0.32	300	94.94	12	3.8	0	0	2	0.63	1	0.32	316
C23-C24	Gallbladder etc.	0	0	269	95.73	11	3.91	0	0	0	0	1	0.36	281
C25	Pancreas	0	0	173	94.54	7	3.83	0	0	3	1.64	0	0	183
C30-C31	Nose, Sinuses etc.	0	0	85	100	0	0	0	0	0	0	0	0	85
C32	Larynx	5	0.92	533	97.98	5	0.92	0	0	0	0	1	0.18	544
C33-C34	Lung etc.	0	0	1456	96.49	45	2.98	0	0	5	0.33	3	0.2	1509
C37-C38	Other Thoracic Organs	0	0	94	94	6	6	0	0	0	0	0	0	100
C40-C41	Bone	1	0.56	171	95.53	6	3.35	0	0	1	0.56	0	0	179
C43	Melanoma of Skin	1	0.75	133	99.25	0	0	0	0	0	0	0	0	134
C44	Other Skin	0	0	45	97.83	1	2.17	0	0	0	0	0	0	46
C45	Mesothelioma	0	0	3	100	0	0	0	0	0	0	0	0	3
C47+C49	Conn. and Soft Tissue	0	0	118	98.33	2	1.67	0	0	0	0	0	0	120
C50	Breast	0	0	155	98.1	2	1.27	0	0	0	0	1	0.63	158
C60	Penis	0	0	121	99.18	1	0.82	0	0	0	0	0	0	122
C61	Prostate	2	0.22	871	96.35	28	3.1	0	0	1	0.11	2	0.22	904
C62	Testis	0	0	102	97.14	1	0.95	0	0	1	0.95	1	0.95	105
C63	Other Male Genital	0	0	4	100	0	0	0	0	0	0	0	0	4
C64	Kidney etc.	0	0	251	92.96	16	5.93	0	0	2	0.74	1	0.37	270
C65	Renal Pelvis	0	0	3	100	0	0	0	0	0	0	0	0	3
C66	Ureter	0	0	6	100	0	0	0	0	0	0	0	0	6
C67	Urinary Bladder	0	0	291	98.98	2	0.68	0	0	1	0.34	0	0	294
C68	Uns. Urinary Organs	0	0	4	100	0	0	0	0	0	0	0	0	4
C69	Eye	1	4.35	21	91.3	1	4.35	0	0	0	0	0	0	23
C70-C72	Brain, Nervous System	2	0.59	327	95.89	8	2.35	0	0	4	1.17	0	0	341
C73	Thyroid	0	0	87	98.86	1	1.14	0	0	0	0	0	0	88
C74	Adrenal Gland	0	0	17	94.44	1	5.56	0	0	0	0	0	0	18
C81	Hodgkins Disease	0	0	133	98.52	1	0.74	0	0	0	0	1	0.74	135
C82-C85	NHL	1	0.17	585	98.98	2	0.34	0	0	0	0	3	0.51	591
C90	Multiple Myeloma	0	0	208	100	0	0	0	0	0	0	0	0	208
C91	Lymphoid Leuk.	0	0	478	100	0	0	0	0	0	0	0	0	478
C92-C94	Myeloid Leukaemia	0	0	464	100	0	0	0	0	0	0	0	0	464
C95	Leukaemia Uns	0	0	26	100	0	0	0	0	0	0	0	0	26
C96	CMD,O and U LHM	0	0	14	100	0	0	0	0	0	0	0	0	14
O&U*	Other and Uns	12	1.17	991	96.59	19	1.85	0	0	2	0.19	2	0.19	1026
	ALL sites	47	0.24	19087	97.95	281	1.44	1	0.01	45	0.23	25	0.13	19486

*O&U includes the Sites(ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number (#) and Proportion (%) of Cancers by site (ICD-10) and Method of Diagnosis:

2015-2020 – Females

ICD10		Clinical		Microscopic		X-Ray Imaging		DCO		Others		Unknown		Total Count
Code	Description	n	%	n	%	n	%	n	%	n	%	n	%	N
C00	Lip	0	0	34	100	0	0	0	0	0	0	0	0	34
C01-C02	Tongue	1	0.15	671	98.97	4	0.59	0	0	2	0.29	0	0	678
C03-C06	Mouth	1	0.11	883	98.99	8	0.9	0	0	0	0	0	0	892
C07-C08	Salivary Gland	0	0	42	95.45	2	4.55	0	0	0	0	0	0	44
C09	Tonsil	0	0	29	100	0	0	0	0	0	0	0	0	29
C10	Oth. Oropharynx	0	0	17	100	0	0	0	0	0	0	0	0	17
C11	Nasopharynx	0	0	27	96.43	1	3.57	0	0	0	0	0	0	28
C12-C13	Hypopharynx	0	0	126	99.21	1	0.79	0	0	0	0	0	0	127
C14	Pharynx Unspecified	0	0	24	96	1	4	0	0	0	0	0	0	25
C15	Oesophagus	0	0	494	98.21	7	1.39	0	0	2	0.4	0	0	503
C16	Stomach	0	0	185	93.43	11	5.56	0	0	1	0.51	1	0.51	198
C17	Small Intestine	0	0	39	97.5	0	0	0	0	0	0	1	2.5	40
C18	Colon	0	0	243	95.29	5	1.96	0	0	5	1.96	2	0.78	255
C19-C20	Rectum	1	0.45	213	95.95	8	3.6	0	0	0	0	0	0	222
C21	Anus and Anal Canal	0	0	41	97.62	1	2.38	0	0	0	0	0	0	42
C22	Liver	0	0	108	94.74	6	5.26	0	0	0	0	0	0	114
C23-C24	Gallbladder etc.	1	0.27	357	97.01	6	1.63	0	0	4	1.09	0	0	368
C25	Pancreas	0	0	112	95.73	5	4.27	0	0	0	0	0	0	117
C30-C31	Nose, Sinuses etc.	0	0	43	97.73	1	2.27	0	0	0	0	0	0	44
C32	Larynx	0	0	65	97.01	2	2.99	0	0	0	0	0	0	67
C33-C34	Lung etc.	1	0.22	426	95.73	17	3.82	0	0	1	0.22	0	0	445
C37-C38	Other Thoracic Organs	0	0	39	95.12	2	4.88	0	0	0	0	0	0	41
C40-C41	Bone	2	1.63	119	96.75	2	1.63	0	0	0	0	0	0	123
C43	Melanoma of Skin	4	2.9	134	97.1	0	0	0	0	0	0	0	0	138
C44	Other Skin	0	0	37	97.37	1	2.63	0	0	0	0	0	0	38
C45	Mesothelioma	0	0	1	100	0	0	0	0	0	0	0	0	1
C47+C49	Conn. and Soft Tissue	0	0	97	100	0	0	0	0	0	0	0	0	97
C50	Breast	7	0.13	5249	98.02	87	1.62	0	0	9	0.17	3	0.06	5355
C51	Vulva	0	0	83	97.65	2	2.35	0	0	0	0	0	0	85
C52	Vagina	0	0	160	99.38	1	0.62	0	0	0	0	0	0	161
C53	Cervix Uteri	2	0.17	1185	98.34	16	1.33	0	0	2	0.17	0	0	1205
C54	Corpus Uteri	0	0	475	98.96	4	0.83	0	0	0	0	1	0.21	480
C55	Uterus Unspecified	0	0	126	99.21	0	0	0	0	0	0	1	0.79	127
C56	Ovary etc.	1	0.12	780	95.01	31	3.78	0	0	3	0.37	6	0.73	821
C57	Other Female Genital	0	0	24	96	0	0	0	0	1	4	0	0	25
C58	Placenta	0	0	2	100	0	0	0	0	0	0	0	0	2
C64	Kidney etc.	0	0	143	94.7	7	4.64	0	0	1	0.66	0	0	151
C66	Ureter	0	0	1	100	0	0	0	0	0	0	0	0	1
C67	Urinary Bladder	0	0	87	97.75	1	1.12	0	0	1	1.12	0	0	89
C68	Uns. Urinary Organs	0	0	7	100	0	0	0	0	0	0	0	0	7
C69	Eye	0	0	20	90.91	2	9.09	0	0	0	0	0	0	22
C70-C72	Brain, Nervous System	0	0	219	96.9	5	2.21	0	0	2	0.88	0	0	226
C73	Thyroid	0	0	224	96.97	5	2.16	0	0	1	0.43	1	0.43	231
C74	Adrenal Gland	0	0	10	100	0	0	0	0	0	0	0	0	10
C81	Hodgkins Disease	1	1.28	77	98.72	0	0	0	0	0	0	0	0	78
C82-C85	NHL	1	0.26	375	98.68	2	0.53	0	0	0	0	2	0.53	380
C90	Multiple Myeloma	0	0	147	100	0	0	0	0	0	0	0	0	147
C91	Lymphoid Leuk.	0	0	234	100	0	0	0	0	0	0	0	0	234
C92-C94	Myeloid Leukaemia	0	0	291	100	0	0	0	0	0	0	0	0	291
C95	Leukaemia Uns	0	0	19	100	0	0	0	0	0	0	0	0	19
C96	CMD,O and U LHM	0	0	14	100	0	0	0	0	0	0	0	0	14
O&U*	Other and Uns	2	0.36	535	96.22	15	2.7	0	0	4	0.72	0	0	556
	ALL sites	25	0.16	15093	97.73	269	1.74	0	0	39	0.25	18	0.12	15444

*O&U includes the Sites (ICD-10: C26, C39, C48, C75, C76, C77, C78, C79, C80, C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number (#) and Proportion (%) of Cancers by site (ICD-10) and detailed microscopic Diagnosis: 2015-20 – Males

ICD10		Primary Histology		Secondary		Cytology		Blood Film		Bone Marrow		Others		Total	
Code	Description	n	%	n	%	n	%	n	%	n	%	n	%	N	%
C00	Lip	176	98.3	1	0.6	2	1.1	0	0	0	0	0	0	179	100
C01-C02	Tongue	2244	97.6	22	1	6	0.3	0	0	0	0	28	1.2	2300	100
C03-C06	Mouth	4726	98.2	18	0.4	21	0.4	0	0	1	0	46	1	4812	100
C07-C08	Salivary Gland	62	89.9	1	1.4	2	2.9	0	0	0	0	4	5.8	69	100
C09	Tonsil	202	97.6	5	2.4	0	0	0	0	0	0	0	0	207	100
C10	Oth. Oropharynx	134	92.4	4	2.8	0	0	0	0	0	0	7	4.8	145	100
C11	Nasopharynx	53	89.8	4	6.8	1	1.7	0	0	0	0	1	1.7	59	100
C12-C13	Hypopharynx	464	97.1	8	1.7	1	0.2	0	0	0	0	5	1	478	100
C14	Pharynx Unspecified	149	98	2	1.3	1	0.7	0	0	0	0	0	0	152	100
C15	Oesophagus	924	96.5	13	1.4	7	0.7	0	0	0	0	14	1.5	958	100
C16	Stomach	294	93	13	4.1	1	0.3	0	0	1	0.3	7	2.2	316	100
C17	Small Intestine	55	96.5	0	0	0	0	0	0	1	1.8	1	1.8	57	100
C18	Colon	466	94.7	16	3.3	4	0.8	0	0	1	0.2	5	1	492	100
C19-C20	Rectum	372	95.9	6	1.5	4	1	0	0	1	0.3	5	1.3	388	100
C21	Anus and Anal Canal	91	98.9	0	0	0	0	0	0	0	0	1	1.1	92	100
C22	Liver	284	89.9	11	3.5	3	0.9	0	0	1	0.3	17	5.4	316	100
C23-C24	Gallbladder etc.	252	89.7	14	5	4	1.4	0	0	0	0	11	3.9	281	100
C25	Pancreas	151	82.5	13	7.1	9	4.9	0	0	4	2.2	6	3.3	183	100
C30-C31	Nose, Sinuses etc.	83	97.6	2	2.4	0	0	0	0	0	0	0	0	85	100
C32	Larynx	514	94.5	13	2.4	5	0.9	0	0	0	0	12	2.2	544	100
C33-C34	Lung etc.	1332	88.3	103	6.8	26	1.7	0	0	0	0	48	3.2	1509	100
C37-C38	Other Thoracic Organs	85	85	4	4	6	6	0	0	0	0	5	5	100	100
C40-C41	Bone	170	95	1	0.6	2	1.1	0	0	0	0	6	3.4	179	100
C43	Melanoma of Skin	128	95.5	4	3	1	0.7	0	0	0	0	1	0.7	134	100
C44	Other Skin	45	97.8	0	0	0	0	0	0	0	0	1	2.2	46	100
C45	Mesothelioma	3	100	0	0	0	0	0	0	0	0	0	0	3	100
C47+C49	Conn. and Soft Tissue	117	97.5	1	0.8	0	0	0	0	0	0	2	1.7	120	100
C50	Breast	152	96.2	2	1.3	0	0	0	0	0	0	4	2.5	158	100
C60	Penis	120	98.4	0	0	0	0	0	0	0	0	2	1.6	122	100
C61	Prostate	851	94.1	20	2.2	11	1.2	0	0	0	0	22	2.4	904	100
C62	Testis	101	96.2	1	1	1	1	0	0	0	0	2	1.9	105	100
C63	Other Male Genital	4	100	0	0	0	0	0	0	0	0	0	0	4	100
C64	Kidney etc.	244	90.4	4	1.5	3	1.1	0	0	0	0	19	7	270	100
C65	Renal Pelvis	3	100	0	0	0	0	0	0	0	0	0	0	3	100
C66	Ureter	6	100	0	0	0	0	0	0	0	0	0	0	6	100
C67	Urinary Bladder	289	98.3	1	0.3	1	0.3	0	0	0	0	3	1	294	100
C68	Uns. Urinary Organs	4	100	0	0	0	0	0	0	0	0	0	0	4	100
C69	Eye	21	91.3	0	0	0	0	0	0	0	0	2	8.7	23	100
C70-C72	Brain, Nervous System	326	95.6	0	0	2	0.6	0	0	0	0	13	3.8	341	100
C73	Thyroid	83	94.3	3	3.4	0	0	0	0	0	0	2	2.3	88	100
C74	Adrenal Gland	16	88.9	1	5.6	0	0	0	0	0	0	1	5.6	18	100
C81	Hodgkins Disease	121	89.6	1	0.7	1	0.7	0	0	11	8.1	1	0.7	135	100
C82-C85	NHL	567	95.9	3	0.5	2	0.3	0	0	11	1.9	8	1.4	591	100
C90	Multiple Myeloma	23	11.1	0	0	0	0	0	0	185	88.9	0	0	208	100
C91	Lymphoid Leuk.	38	7.9	0	0	0	0	0	0	440	92.1	0	0	478	100
C92-C94	Myeloid Leukaemia	29	6.3	0	0	0	0	1	0.2	434	93.5	0	0	464	100
C95	Leukaemia Uns	2	7.7	0	0	0	0	0	0	24	92.3	0	0	26	100
C96	CMD, O and U LHM	3	21.4	0	0	0	0	1	7.1	10	71.4	0	0	14	100
O&U*	Other and Uns	169	16.5	761	74.2	22	2.1	0	0	0	0	74	7.2	1026	100
	All Sites	16748	85.9	1076	5.5	149	0.8	2	0	1125	5.8	386	2	19486	100

*O&U includes the Sites(ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



National Cancer Registry Program



Population Based Cancer Registry

Ahmedabad Urban Report 2015-2020

Number (#) and Proportion (%) of Cancers by site (ICD-10) and detailed microscopic Diagnosis: 2015-20 – Females

ICD10		Primary Histology		Secondary Histology		Cytology		Blood Film		Bone Marrow		Others		Total	
Code	Description	n	%	n	%	n	%	n	%	n	%	n	%	N	%
C00	Lip	34	100	0	0	0	0	0	0	0	0	0	0	34	100
C01-C02	Tongue	667	98.4	2	0.3	3	0.4	0	0	0	0	6	0.9	678	100
C03-C06	Mouth	878	98.4	4	0.4	4	0.4	0	0	1	0.1	5	0.6	892	100
C07-C08	Salivary Gland	40	90.9	3	6.8	0	0	0	0	0	0	1	2.3	44	100
C09	Tonsil	28	96.6	0	0	0	0	0	0	0	0	1	3.4	29	100
C10	Oth. Oropharynx	17	100	0	0	0	0	0	0	0	0	0	0	17	100
C11	Nasopharynx	27	96.4	1	3.6	0	0	0	0	0	0	0	0	28	100
C12-C13	Hypopharynx	124	97.6	2	1.6	1	0.8	0	0	0	0	0	0	127	100
C14	Pharynx Unspecified	24	96	0	0	0	0	0	0	0	0	1	4	25	100
C15	Oesophagus	491	97.6	0	0	4	0.8	0	0	0	0	8	1.6	503	100
C16	Stomach	179	90.4	4	2	3	1.5	0	0	3	1.5	9	4.5	198	100
C17	Small Intestine	39	97.5	0	0	0	0	0	0	0	0	1	2.5	40	100
C18	Colon	239	93.7	6	2.4	2	0.8	0	0	0	0	8	3.1	255	100
C19-C20	Rectum	206	92.8	5	2.3	3	1.4	0	0	0	0	8	3.6	222	100
C21	Anus and Anal Canal	40	95.2	0	0	1	2.4	0	0	0	0	1	2.4	42	100
C22	Liver	101	88.6	6	5.3	2	1.8	0	0	3	2.6	2	1.8	114	100
C23-C24	Gallbladder etc.	328	89.1	24	6.5	2	0.5	0	0	0	0	14	3.8	368	100
C25	Pancreas	98	83.8	10	8.5	4	3.4	0	0	1	0.9	4	3.4	117	100
C30-C31	Nose, Sinuses etc.	42	95.5	0	0	1	2.3	0	0	0	0	1	2.3	44	100
C32	Larynx	63	94	1	1.5	0	0	0	0	0	0	3	4.5	67	100
C33-C34	Lung etc.	397	89.2	22	4.9	9	2	0	0	1	0.2	16	3.6	445	100
C37-C38	Other Thoracic Organs	34	82.9	0	0	6	15	0	0	0	0	1	2.4	41	100
C40-C41	Bone	119	96.7	0	0	1	0.8	0	0	0	0	3	2.4	123	100
C43	Melanoma of Skin	132	95.7	1	0.7	1	0.7	0	0	0	0	4	2.9	138	100
C44	Other Skin	36	94.7	1	2.6	0	0	0	0	0	0	1	2.6	38	100
C45	Mesothelioma	1	100	0	0	0	0	0	0	0	0	0	0	1	100
C47+C49	Conn. and Soft Tissue	97	100	0	0	0	0	0	0	0	0	0	0	97	100
C50	Breast	5157	96.3	65	1.2	14	0.3	0	0	0	0	119	2.2	5355	100
C51	Vulva	79	92.9	2	2.4	2	2.4	0	0	0	0	2	2.4	85	100
C52	Vagina	159	98.8	1	0.6	1	0.6	0	0	0	0	0	0	161	100
C53	Cervix Uteri	1171	97.2	6	0.5	9	0.7	0	0	6	0.5	13	1.1	1205	100
C54	Corpus Uteri	470	97.9	3	0.6	2	0.4	0	0	2	0.4	3	0.6	480	100
C55	Uterus Unspecified	125	98.4	0	0	1	0.8	0	0	0	0	1	0.8	127	100
C56	Ovary etc.	711	86.6	54	6.6	10	1.2	0	0	17	2.1	29	3.5	821	100
C57	Other Female Genital	22	88	2	8	0	0	0	0	0	0	1	4	25	100
C58	Placenta	2	100	0	0	0	0	0	0	0	0	0	0	2	100
C64	Kidney etc.	143	94.7	2	1.3	1	0.7	0	0	0	0	5	3.3	151	100
C66	Ureter	1	100	0	0	0	0	0	0	0	0	0	0	1	100
C67	Urinary Bladder	84	94.4	1	1.1	2	2.2	0	0	0	0	2	2.2	89	100
C68	Uns. Urinary Organs	7	100	0	0	0	0	0	0	0	0	0	0	7	100
C69	Eye	19	86.4	1	4.5	0	0	0	0	0	0	2	9.1	22	100
C70-C72	Brain, Nervous System	216	95.6	1	0.4	3	1.3	0	0	0	0	6	2.7	226	100
C73	Thyroid	217	93.9	3	1.3	4	1.7	0	0	0	0	7	3	231	100
C74	Adrenal Gland	10	100	0	0	0	0	0	0	0	0	0	0	10	100
C81	Hodgkins Disease	72	92.3	0	0	1	1.3	0	0	4	5.1	1	1.3	78	100
C82-C85	NHL	361	95	4	1.1	1	0.3	1	0.3	8	2.1	5	1.3	380	100
C90	Multiple Myeloma	17	11.6	1	0.7	0	0	0	0	129	87.8	0	0	147	100
C91	Lymphoid Leuk.	14	6	0	0	0	0	0	0	220	94	0	0	234	100
C92-C94	Myeloid Leukaemia	18	6.2	0	0	0	0	1	0.3	272	93.5	0	0	291	100
C95	Leukaemia Uns	1	5.3	0	0	0	0	0	0	18	94.7	0	0	19	100
C96	CMD,O and U LHM	2	14.3	0	0	0	0	0	0	12	85.7	0	0	14	100
O&U*	Other and Uns	122	21.9	393	70.7	8	1.4	0	0	3	0.5	30	5.4	556	100
	All Sites	13681	88.6	631	4.1	106	0.7	2	0	700	4.5	324	2.1	15444	100

*O&U includes the Sites(ICD-10:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97)



ADDRESS FOR COMMUNICATION

**DEPARTMENT OF COMMUNITY ONCOLOGY AND MEDICAL RECORDS
The Gujarat Cancer and Research Institute,
(M.P. Shah Cancer Hospital), New Civil Hospital Campus, Medicity,
Asarwa, Ahmedabad - 380016, GUJARAT, INDIA**

Phone: +91 79 22688239, +91 79 22688257

E-Mail: anand.shah@gcriindia.org, pbcrAhmedabad@gmail.com